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ABSTRACT
Subunit Interactions Of Recombinant HIV-1 Reverse 
Transcriptase With Mutations At L289
Jacquelyn Ross Smith 
Old Dominion University, 1994 
Director: Dr. Laura K. Moen
Reverse transcriptase (RT) is a dimeric enzyme required for replication of the 
human immunodeficiency virus (HIV). If the subunits of the RT dimer are dissociated, 
the enzyme is no longer active; therefore, identification of subunit binding sites could 
lead to potential targets for antiviral therapy. In order to identify where subunit binding 
of RT occurs, mutations were made at leucine (L) 289, a residue believed to be involved 
in dimerization through hydrophobic interactions with other leucines. L289 is the central 
leucine of a leucine repeat sequence which resembles a leucine zipper protein-DNA bind­
ing motif. Two mutations, leucine to arginine (L289R) and leucine to proline (L289P), 
were created using PCR mutagenesis. The mutations in the RT gene were verified by 
DNA sequencing, and cloned into a yeast expression vector using recombinant DNA 
techniques. The RT mutants were purified from yeast and compared to wild type RT in 
terms of specific activity, subunit dissociation, and subunit association using RT poly­
merase activity assays, fluorescence studies, and analytical gel filtration. Only the L289P 
mutant showed significantly less specific activity than wild type RT, and neither mutation 
affected RNase H activity. Both mutants dissociated into monomers slightly more easily 
than wild type RT, and both mutants were slower to associate to form dimers than wild 
type RT. L289P dimers dissociated slightly more easily than L289R dimers and were 
slower to reassociate. These mutations had only moderate effects on subunit interactions.
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If leucine 289 was part of a leucine zipper and directly involved in subunit binding, then 
both mutations would have had much greater effects on subunit interactions. Also, since 
RT subunit interactions are known to be hydrophobic in nature, the mutation to arginine, 
which is very hydrophilic, was expected to have a greater effect on dimerization than the 
proline mutation. However, the opposite was observed and the L289P mutation had a 
greater effect than the L289R mutation. These results are consistent with recent 3- 
dimensional computer modeling studies which indicate that leucine 289 is too far from 
the dimer interface to be involved in subunit binding. Leucine 289 is probably very 
important for maintaining secondary structure and proper folding of the enzyme, but it is 
not directly involved in subunit interactions.
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INTRODUCTION
Human Immunodefficiency Virus Type-1 (HIV-1) has been identified as the 
causative agent of AIDS (1,2). HIV-1 is a member of the lentivirus group of slow acting 
retroviruses which uses reverse transcription to replicate. The virus may take up to 12 
years before causing disease (3), but when it does it is always fatal. There is no cure on 
the horizon and currently no effective treatment (4). The way by which HIV causes AIDS 
is very complicated and can occur by one or more of several direct or indirect means (3). 
HIV infection always results in severe immuno-suppression usually followed by 
opportunistic infections (5). Development of an effective treatment for HIV will require 
reduction in viral replication and improvements in immune function (5). The life cycle of 
the virus can be divided into 6 steps: 1) binding of virus to host cell membrane and release 
of viral core contents into cell cytoplasm, 2) reverse transcription, 3) migration of viral 
DNA to nucleus and integration with host cell's DNA, 4) viral transcription, 5) viral protein 
synthesis and processing, 6) virion assembly, release of virus from cell, and maturation 
(6). Each of these steps are being investigated as targets for HIV drug therapy (Figure 1).
Reverse transcriptase (RT) is an enzyme required for reproduction of HIV. RT 
uses three different functional activities to convert the single-stranded RNA genome into 
double-stranded DNA so that it can be incorporated into the host cells genome (7). The 
first function uses RNA-dependent DNA polymerase activity to copy the single, plus- 
stranded genomic RNA into minus-stranded DNA using cellular tRNA Lys as a primer. 
The second function uses ribonuclease hybrid (RNase H) activity to degrade the viral RNA 
template bound to the newly synthesized DNA except for a small piece of the viral RNA
1
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Figure 1. Diagram showing the main steps in the life cycle of HIV-1 which are potential 
targets for HIV drug therapy.
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which will act as primer for the third step of reverse transcription. This third activity, and 
the final step of reverse transcription, is DNA-dependent DNA polymerase activity which 
synthesizes the complimentary, plus-strand of viral DNA. The viral genomic material is 
now double stranded DNA which can be incorporated into the host cell genome where it 
will be transcribed along with the host's own DNA (7). These three steps require very 
different and specific activities which are carried out by two different but interdependent 
functional domains, the polymerase domain and the RNase H domain (8, 9, 10, 11). 
Reverse transcriptase has been studied extensively since the enzyme was discovered in 
1970 (12, 13); and since HIV was identified as the causative agent of AIDS, HIV-1 RT 
has been the most thoroughly characterized of all known types of RT. However, we still 
do not know enough to design an effective drug to specifically inhibit this enzyme.
Since RT is the only enzyme required for reverse transcription, which is an 
essential step in the life cycle of this virus, RT is a primary target for anti-viral drug therapy
(14). Currently there are only three FDA approved drugs for the treatment of AIDS and all 
three are nucleoside analogs which inhibit RT by chain termination through competitive 
inhibition of the dNTP substrate (14). These analogs are 3' -azidothymidine (AZT), 2',3' 
-dideoxyinosine (ddl), and 2',3' - dideoxycytidine (ddC). These drugs have various toxic 
side effects because they are not specific enough and will inhibit host cell DNA 
polymerases as well as HIV-1 RT (15). There are several other nucleoside analogs which 
are currently undergoing clinical trials including d4T, 3TC, 3' -fluoro-thymidine (FLT), 
and 9-(2-Phosphonomethoxyethyl)-adenine (PMEA) (5). There are non-nucleoside analog 
inhibitors of HIV-1 RT such as the tetrahydroimidazo-[4,5,l]-[l,4]-benzodiazepin-2-(lH)- 
one and thione (TIBO) derivatives (15), nevirapine, pyridones, and more (5). These 
substances appear to be very specific for HIV-1 RT and may involve an allosteric binding 
site; however, neither the mechanism of inhibition nor possible side effects are known
(15). Another problem encountered with RT inhibitors is the formation of drug-resistant 
variants of HIV. HIV shows extreme hyper-mutability due to the high error rate of HIV-1
3
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RT (16). Consequently, mutants arise which are no longer susceptible to most drug 
inhibitors. Current treatments and therapies in development have been reviewed recently 
(5). The more we know about the structure and function of HIV-1 RT, including 
knowledge of conserved and essential sequences of each domain, the more likely we will 
be able to design safe and effective drugs to inhibit this deadly virus. One aspect of the 
structure of RT that is essential for activation of the enzyme is dimerization. If we can 
determine where these subunit interactions take place then we can design a method for 
blocking these binding sites which would prevent dimerization and inhibit activity of the 
enzyme.
RT is a product of the polymerase (pol) gene of HIV which also codes for protease 
(5’end) and integrase (3’end) (17) as shown in Figure 2. RT is expressed as a 560 amino 
acid polypeptide and has an apparent molecular weight of 66,000; however, RT purified 
from virions is a dimer consisting of two subunits, a 66kD subunit (p66) and a 51kD 
subunit (p51), which have the same N-terminal sequences (18,19). The smaller subunit, 
p51 is derived from the larger p66 subunit through proteolytic processing by HIV-1 
protease at a specific site, Phe 440 (20, 21). The C-terminal region cleaved from p66 
contains the RNase H domain so p51 does not have any RNase H activity (22). The 
polymerase domain is located in the N-terminal region of both p66 and p51 (9, 23) (see 
Figure 3), but only the polymerase domain of the p66 subunit appears to be catalytically 
active (24, 25). It was found that, although recombinant HIV-RT does not contain viral 
protease, it still produces equimolar amounts of p66 and p51, indicating that proteolytic 
processing of RT can also be carried out by host cell proteases (26). By including 
protease inhibitors in the purification procedure researchers can obtain uncleaved p66 in 
equilibrium between monomer and homodimer forms (20). Even though the heterodimer 
p66/p51 has only one catalytically active polymerase domain, it is still the most active form 
of the enzyme (27). Recent research suggests that the p51 subunit serves to increase the 
processivity of p66/p51 (28). Increased enzyme processivity may be due to either stronger
4
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Figure 2. Schematic diagram showing that the three HIV-1 enzymes: protease, reverse 
transcriptase (RT), and integrase come from the pol gene of HIV-1. R T i s m a d e u p o f  
three domains: the polymerse domain, the tether domain, and the RNase H domain.
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Figure 3. Schematic diagram of HIV-1 reverse transcriptase showing the domain 
arrangement and protease cleavage site which forms the p51 subunit by cleavage near 
the C-terminus of p66.
fcc.. •
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primer-template binding or better conformation of the enzyme active site. As a result of the 
increased processivity, p66/p51 has twice the specific activity as p66/p66 with only half as 
many catalytically active polymerase domains (28).
Researchers have observed an apparent connection between dimer stability or 
dimerization and enzyme activity (20, 27, 29, 30, 31). Dimer stability can be defined as 
the percentage of dimeric enzyme versus monomeric enzyme. Dimerization has been 
analyzed using HPLC gel filtration, analytical ultracentrifugation, polymerase activity, and 
fluorescence. It was found that the subunit species involved, either pure p66 or pure p51, 
or a mixture of p66 and p51, determines how stable the dimer is. Enzyme activity studies 
show that p66/p51 is the most stable dimeric form of the enzyme and has the greatest 
amount of activity (20). Homodimer, p66/p66, is less stable and has 20% less enzyme 
activity than heterodimer. Homodimer, p51/p51, has 10-20% less activity than p66/p66 
(20). Accurate determination of the dissociation constant for heterodimer has been difficult 
and is usually achieved by either of two methods. The subunits of the heterodimer can be 
dissociated using 17% acetonitrile without causing them to unfold. When the concentration 
of acetonitrile is diluted ten-fold re-association of subunits and restoration of enzyme 
activity is observed (29). Another technique is to use recombinant p66 and p51 that are 
separately expressed and purified before combining them to observe association. 
Homodimer, p66/p66, is less stable than p66/p51 and appears to exist in a monomer-dimer 
equilibrium (27). Restle and coworkers (29) used HPLC gel filtration to study 
reassociation of subunits which were first dissociated with 17% acetonitrile and found the 
Ka of purified recombinant p66 to be 2.3 x 105 M -1. They estimated the Ka of p66/p51 to 
be at least 109 M_1 (29). Three years later the same lab, using intrinsic protein fluor­
escence, determined Kj of the heterodimer to be 4x l010 M_1 (32). Using analytical 
ultracentrifugation, Becerra and coworkers (33) determined Ka for p66 to be 5.1 x 10 4 M 
-1 and for p66/p51 heterodimer to be significantly greater at 4.9 x 105 MM , which is much 
less than what Restle and coworkers (29) determined. The difference in results may be due
7
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not only to the fact that two different methods were used for measuring dimerization, but 
also because the RT forms used were obtained by different methods and the p51 subunit 
was slightly different in each case. Becerra's group used separately expressed cloned p66 
and p51, whereas Restle's group used p51 derived from p66 by proteolytic cleavage 
forming the C-terminus found in vivo . Restle's construct turned out to be 15 residues 
longer than Becerra's cloned p51. The p51/p51 homodimer, formed when using a cloned 
recombinant gene coding for the 51 kD subunit, is very unstable and rapidly dissociates 
into monomers (20, 29, 30). Restle and coworkers determined the Ka for p51 to be 1.5 x 
103 NT1 (29). All of these kinetic studies on the dimerization of HIV RT demonstrate that 
1) the form of enzyme which has the greatest polymerase activity, p66/p51, also forms the 
most stable dimers, 2) the form of enzyme which has the least polymerase activity, purified 
recombinant p51, forms the least stable dimers, 3) purified recombinant p66 forms dimers 
that are less stable than p66/p51 and have less activity, and 4) p66 forms homodimers that 
are more stable than p51 homodimers and have greater enzyme activity.
Anderson and Coleman (34) correlated changes in enzyme activity with changes in 
conformation observed when p66 is cleaved to form p66/p51 using circular dichroism. 
They observed such a big change in conformation that it indicates not only the formation of 
a new species, p51, but also that the remaining uncleaved p66 subunit also undergoes 
conformational change. These observations support the theory that, in vivo, immediately 
after p66 is formed it associates into homodimers which are the target of HIV protease. As 
soon as one of the subunits is cleaved to form p51 the other p66 subunit folds, blocking the 
protease cleavage site resulting in only the p66/p51 heterodimer (35). The Anderson and 
Coleman research (34) also supports the theory that half the polymerase active sites are 
inactivated by formation of heterodimer but that this is offset by a much greater increase in 
binding affinity of heterodimer for primer-template.
Some information on the nature of the subunit interactions involved in dimerization 
has been obtained. Subunit interactions appear to be noncovalent and hydrophobic, based
8
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on the behavior of the enzyme as a function of salt concentration and enzyme concentration 
(27, 29, 33, 36). Dimer stability and enzyme activity are favored in high salt buffers 
containing, for example, either 1M ammonium phosphate (27), 60mM sodium pyrophos­
phate (27), or 200mM sodium chloride (33). These results suggest that the subunit inter­
actions involve hydrophobic effects because such high ionic strength solutions would 
inhibit ionic interactions and enhance hydrophobic effects. The concentration of RT in a 
sample also affects dimer stability and RT activity. Restle and coworkers (29) found that in 
a dilute solution homodimer (p66/p66 or p51/p51) dissociates relatively rapidly into 
monomers. When samples containing primarily monomers were concentrated, they 
showed an increase in the dimer to monomer ratio and an increase in enzyme activity (29). 
Similar results were obtained by Deibel and coworkers (36) who found that p66 isolated 
under dilute concentrations (less than 0.5 mg/ml) was primarily monomeric and had low 
activity, but when the p66 solution was concentrated it showed increased activity.
The presence of template-primer substrate in the enzyme solution also appears to 
affect enzyme stability. Rowley and coworkers (27) observed that when template-primer 
was added to a solution of p66, the activity of the enzyme was stabilized and did not 
decrease as it did in an enzyme solution which did not contain template-primer. The Divita 
study using fluorescence also observed an increase in dimer stability when template-primer 
was added to the enzyme solution (32). These results indicate that dimerization is 
maintained through the formation of a dimer/template-primer complex in which both of the 
subunits of the dimer bind to the template-primer. Several researchers support the theory 
that a hydrophobic dimer interface forms part of a template-primer binding site (35, 33, 
37). Studies using fluorescence to observe dimer association and dissociation showed a 
25% increase in tryptophan fluorescence when dimers dissociate into monomers. These 
researchers suggested that the tryptophans (7 in region 398 to 414) are highly hydrophobic 
and may be directly involved in the protein-protein interactions of dimerization (32,38).
Mg2+ has also been shown to be involved in subunit interactions by increasing the
9
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association rate by 100 fold (32). Divita and coworkers (32) suggest the Mg2+ may either 
induce a conformational change which supports dimerization, or may be directly involved 
in protein-protein interactions. There are two metal binding sites in a region of the RNase 
H domain which has previously been shown to be involved in protein-protein interactions 
(39).
It is still not known which specific amino acids participate in subunit binding. The 
relationship between subunit species and dimer stability suggest that one RNase H domain, 
as is found in p66/p51, is needed for subunit binding because p51/p51 which has no 
RNase H domains is very unstable; but that two RNase H domains, as is found in 
p66/p66, hinders subunit binding. Becerra and coworkers (33) used immunoprecipitation 
to analyze binding between p66 and different p66 polypeptide segments corresponding to 
p29 (N-terminus), pl5 (C-terminus), and p51. They found that neither p29 nor pl5 
showed any binding to p66; only p51 bound to p66, indicating that the central region of 
p66, residues 252-428, is required for subunit binding (33). A recent study on the effects 
of certain monoclonal antibodies on heterodimer formation found that three regions are 
involved in subunit interactions: 1) amino acids 230-300, 2) amino acids 350-428, and 3) 
residues around amino acid 540 (39). Baillon and coworkers (1991), analyzing the amino 
acid sequence of RT in the central region, found a leucine repeat sequence which resembled 
the leucine zipper motif found in certain DNA binding proteins. Site-directed mutagenesis 
of the leucines was used to determine if they were involved in dimerization (40). This 
research was being carried out at the same time as my own research in which I also mutated 
one of the leucine residues in this region, so their results will be compared to my results in 
the discussion section of this paper. Briefly, they found that L289K-P66 was unable to 
form dimers with itself or with wild-type p66, or with L289K-p51. They believe that the 
leucine repeat motif in the p66 subunit is critical to formation of the heterodimer. How­
ever, wild type p66 could dimerize with mutant L289K-p51 suggesting that this residue in 
the p51 subunit is not at the hydrophobic protein-protein interface and is therefore not
10
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
critical to formation of the heterodimer (40).
In June of 1992 the crystal structure of HIV-1 RT complexed with the drug 
Nevirapine was published (41). The researchers found that the polymerase domain of p66 
subunit is analogous to the Klenow fragment of E. coli DNA polymerase I. However, the 
p51 subunit, which has the identical sequence of p66 minus the RNase H domain, has a 
very different tertiary structure. It has been shown through research that p51 does not 
appear to be involved in the catalytic function of polymerization (24,25), but it has been 
postulated to be necessary for template-primer binding (41) and several researchers have 
observed that p66/p51 has a greater template-primer binding affinity than p66/p66. The 
crystal structure shows that p66 has a large cleft, which p51 does not have, and it is this 
cleft which is believed to be the catalytic site (41). Each subunit is divided into four 
subdomains: 1) fingers, 2) palm, 3) thumb, which are named for their orientation in p66 
relative to a right hand, and 4) a connection subdomain which corresponds to what was 
previously called the tether domain. The crystal structure shows that the tip of the fingers 
subdomain of p51 is adjacent to the palm subdomain of p66. It also shows that both of the 
connection subdomains of p66 and p51 are closely associated, and the thumb of p51 
contacts the RNase H domain of p66 (41). Which of these associations is necessary for 
subunit binding and/or template-primer binding is not known.
The work in this study correlates specific changes in the amino acid sequence of RT 
with changes in subunit interactions and enzyme function. Before using site-directed 
mutagenesis to analyze structure-function relationships involved in the dimerization of 
HIV-1 RT, the amino acid sequences of different RT clones were compared to identify 
conserved residues. The RT amino acid sequences of the three original HIV-1 isolates (42, 
43, 44), as well as several several sequences obtained from NIH's GenBank, were 
compared. These studies showed that 30 out of the 560 amino acids of HIV-1 RT were 
variable among different RT clones, which is not surprising since it is known to be a highly 
mutable protein (45). The sequence comparison studies also showed that the amino acids
11
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in the leucine repeat region were highly conserved. Since this leucine repeat sequence is 
located in one of the regions identified as a possible subunit binding site (33,39), and since 
it resembles a leucine zipper which involves hydrophobic subunit interactions, it will be the 
target of mutagensis for this research. These changes, when interpreted with the recently 
available crystal data and activity analyses, will identify where subunit interactions take 
place. This information will contribute to the overall understanding of HIV-1 RT structure 
and function and will provide a possible target for drug design efforts to combat AIDS and 
possibly other retroviral diseases.
12
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MATERIALS
Yeast and Bacteria Cultures
Saccharomyces cerevisiae strain AB110, Dr. Moen's -70°C stock cultures 
Saccharomyces cerevisiae strain XS95-6C, from U.C. Berkely Yeast Genetic Stock 
Center
Escherichia coli (E. coli ) strain HB101, Dr. Moen's -70°C stock cultures 
Plasmid
Yeast plasmid expression vector containing gene for wild type reverse transcriptase, 
pAB24/RT5, cloned in yeast strain AB110, Dr. Moen's -70°C stock cultures
Chemicals
Acetonitrile - Fisher
Acrylamide, electrophoresis grade - Fisher 
Affi-Gel Blue 100-200 Mesh (wet) 75-150 |i- BioRad 
Agar, Bacto - Difco
Agarose, Seakem LE, GTG, and NuSieve - FMC BioProducts
Albumin Standard - Pierce
Amino Acids - Sigma
Ammonium Persulfate (APS) - Fisher
Ammonium Sulfate - Fisher
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Ampicillin, Sodium Salt - Sigma
AmpliWax PCR Gem 100 pellets - Perkin Elmer Cetus
BisAcrylamide, electrophoresis grade - Fisher
Bovine Serum Albumin (BSA), nuclease free - Promega
Bromophenol Blue - BioRad
1-Butanol - Fisher
Calcium Chloride (CaCl2), Dihydrate - Mallinckrodt
Cesium Chloride - Stratagene
Chloroform - EM Science
Coomassie Brilliant Blue R-250 - BioRad
Coomassie Plus Protein Assay Reagent - Pierce
Dextrose, Bacto - Difco
Ethylene diamine tetraacetate-2H20 (EDTA) - Fisher
Dithiothreitol (DTT) electrophoresis grade - Fisher
Ethidium Bromide (EtBr) - ICN Biochemical
Ethanol (ETOH), 100% - AA PER Alcohol and Chemical
ETOH, 95% - McCormick Distilling
Ficoll 400 - Sigma
Glacial Acetic Acid - Fisher
Glycerol, enzyme grade - Fisher
Glycine, tissue culture grade - Fisher
Hydrochloric Acid (HC1) - EM Science
Isopropanol - EM Science
Isoamyl alcohol - EM Science
p-Mercaptoethanol (pME), electrophoresis grade - Fisher 
Magnesium chloride (MgCh), Hexahydrate - EM Science 
Methanol, HPLC grade - Fisher
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Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
PI 1 cellulose phosphate - Whatman 
Phenylmethylsulfonyl Fluoride (PMSF) - Sigma 
PEG3350 - ICN Biochemical 
Peptone, Bacto - Difco 
Phenol - Fisher
Potassium Chloride (KC1) - Mallinckrodt 
Protein Standards: Gel Filtration Standards - BioRad 
SDS-PAGE Standards - BioRad 
Processing Chemicals, Kodak GBX Developer and Replenisher - Sigma 
Processing Chemicals, Kodak GBX Fixative and Replenisher - Sigma 
Rainex - Unelko
Scintillation Cocktail, CytoScint - ICN Biochemical
Sigmacote - Sigma
Sodium Acetate - Aldrich
Sodium Azide - Sigma
Sodium Chloride (NaCl) - EM Science
Sodium Dodecyl Sulfate (SDS) - Fisher
Sodium Hydroxide (NaOH) - Mallinckrodt
Sodium Pyrophosphate - Fisher
Sorbitol - Fisher
TEMED - BioRad
Trichloro-acetic acid (TCA) - Fisher 
Tris Base - Fisher
Triton X-100 - Boehringer Mannheim 
Tryptone, Bacto - Difco 
Uracil - Sigma 
Urea - Stratagene
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Xylene Cyanole FF, electrophoresis grade - BioRad 
Yeast Extract, Bacto - Difco 
Yeast Nitrogen Base w/o Amino Acids - Difco 
YPD powder - Difco
Enzymes
AMV-RT (8,000 U/ml) - Promega
p-Glucuronidase, 1,000,000 U dry powder (glusulase) - DuPont





AlwN-1 - New England BioLabs
Restriction Enzyme Buffers B, C, D - Promega
Pfii DNA polymerase - Stratagene
pfii Buffer 10X - Stratagene
Ligase and Ligase Buffer - Promega
Nucleotides
Lambda DNA Bste Digest Molecular Weight Marker - Sigma 
Synthetic oligonucleotide primers, reconstituted to 50|lM concentrations - Midland 
Certified Reagent Company 
2' - Deoxyadenosine-5'-Triphosphate (dATP), lOmM - Sigma 
2’ - Deoxycytidine-5'-Triphosphate (dCTP), lOmM - Sigma 
2' - Deoxyguanosine-5'-Triphosphate (dGTP), lOmM - Sigma 
2' - Deoxythymidine-5'-Triphosphate (dTTP), lOmM - Sigma
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[Methyl, 1', 2', - 3H] -Thymidine-5-Triphosphate ([3H]-dTTP), 1.0 mCi/ral - Amersham
(rA)-(dT) 12-18 Template-Primer - Pharmacia
poly(dT) - Pharmacia
poly [8-3H] (rA) - Amersham
Kits
GeneClean- Biol01,Inc.
Silver Sequence - Promega
Media, Buffers, Solutions (All solutions made with milli-Q H 2O and stored at room 
temperature unless otherwise noted)
YPD Medium, 1 liter: Mix and autoclave 20gms peptone, lOgms yeast extract, and
920mls H 2O. Add 50mls of separately autoclaved 20% dextrose, 25mls of filter 
sterilized 0.2% adenine, and 5mls of filter sterilized 1% tryptophan.
Leucine minus rich medium, 1 liter: Combine 10 mis Yeast Nitrogen Base (10X), 0.5 g 
leucine minus amino acid supplement (0.8g adenine, 0.6g tyrosine, 0.6g lysine, 
0.6g uridine, l.Og phenylalanine, 0.4g tryptophan, 0.4g methionine, 0.4g arginine, 
0.4g histidine) 5mls l%tryptophan, 25mls 0.2% adenine, 8mls 5% threonine, 
400mls 20% glucose and H2O to 1 liter. Filter sterilize.
Leucine minus selective medium, 1 liter: first mix and autoclave 5g ammonium sulfate, 
1.7g yeast nitrogen base, 20g dextrose, lg YPD powder, 600ml H 2O. In a 
separate container mix and filter sterilize 0.088g tryptophan, 0.127g adenine, 0.4g 
threonine, 0.058g tyrosine, 0.058g lysine, 0.058g uridine, 0.096g phenylalanine, 
0.038g methionine, 0.038g arginine, 0.038g histidine, O.lg aspartic acid, O.lg 
glutamic acid, 0.39g serine, 0.155g valine, and 0.02g uracil and 400mls of H 2O. 
Once the autoclaved portion has cooled slightly, add the filtered portion and swirl 
to mix.
17
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Leucine minus selective regeneration agar, 500mls: First mix and autoclave 2.5g
ammonium sulfate, 0.85g yeast nitrogen base, lOg dextrose, 250mls 2M sorbitol, 
0.5g YPD powder, 15g agar 50ml H 2O. In a separate container mix and filter 
sterilize 0.044g tryptophan, 0.0635g adenine, 0.2g threonine, 0.029g tyrosine, 
0.029g lysine, 0.029g uridine, 0.048g phenylalanine, 0.019g methionine, 0.019g 
arginine, 0.019g histidine, 0.05g aspartic acid, 0.05g glutamic acid, 0.195g serine, 
0.0775g valine, and O.Olg uracil and 190mls of H2O. Once the autoclaved 
portion has cooled slightly, add the filtered portion and swirl to mix.
LB Medium, 1 liter: Combine lOg Bacto-tryptone, 5g Bacto-yeast extract, lOg NaCl, and 
H2O to 1 liter. Autoclave 15 minutes.
LB selective medium, 1 liter: same as above except add 4ml of filter sterilized 
ampicillin (25mg/ml) when broth has cooled.
For solid media add 20g agar to 1 liter of liquid medium before autoclaving, pour plates 
before medium solidifies.
Yeast Breaking Buffer, for plasmid prep: 2% Triton X-100,1% SDS, lOOmM Na Cl, 
lOmM Tris-Cl pH 8.0,1 mM EDTA 
Disruption Buffer for mini-multiple protein preps: 20mM Tris-Cl pH 7.9, 5% glycerol, 
lOmM MgCl2, ImM EDTA, ImM DTT, 0.3M ammonium sulfate, ImM PMSF 
Lysis Buffer for large protein prep: 50 mM Tris-Cl pH 7.5,20% glyceral, lOOmM KC1, 
0.1% Triton-X 100,4mM EDTA, 2 mMp mercaptoethanol, ImM PMSF 
Reverse Transcriptase Buffer (RTB): 50 mM Tris-Cl pH 7.5, 20% glyceral, 50mM KC1, 
0.1% Triton-X 100,4mM EDTA, 2 mMp mercaptoethanol (add ImM PMSF 
during purification)
RT Activity Assay Buffer (10X): 1M Tris pH8.5,1M MgCl2,4MKC1,1M DTT, 10% 
Triton-X 100
RT Activity Assay Stop Solution: 10% TCA, lOmM Sodium Pyrophosphate 
RT Enzyme Diluent: 20pl 10X RT Activity Assay Buffer, 2\i\ BSA (lOmg/ml), and
18
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p-Glucuronidase: add l l . l l lm ls  H2O to l,000,000u powder to make 90,000 U/ml final 
concentration, store at -20° C 
1M sorbitol, autoclave 
2M sorbitol, autoclave
CaCl2 solution: 0.1M Tris-Cl, pH7.4 and 0.1M CaCl2 , autoclave 
Sorbitol/CaCl2 solution: 1M sorbitol, lOmMTris-Cl pH7.4, lOmM CaCl2 , autoclave 
PEG/CaCh solution: 45% PEG3350, lOmMTris-Cl pH7.4, lOmM CaCh , filter sterilize 
1M Tris-Cl pH 8.0 
1M Tris-Cl pH 7.5
TE Buffer pH 8.0: lOmM Tris-Cl (pH 8.0), ImM EDTA (pH 8.0)
TAE Buffer (50X): 2M Tris- Acetate, 50mM EDTA
TBE Buffer (10X, 1 liter): Combine 108g Tris Base, 55g Boric Acid, 40ml 0.5M EDTA 
pH8.0, and add H2O to 1 liter 
Ethidium Bromide: lOmg/ml stock solution, stored at 4°C, wrapped in foil 
Phenol buffered with 0.1 M Tris-Cl pH 8.0, stored in dark bottle at 4°C 
Chloroform: Isoamyl Alcohol mixed 24:1 
Phenol:Chloroform: Isoamyl Alcohol mixed 25:24:1 
3M Sodium Acetate, pH ajusted to 5.2 with glacial acetic acid 
70% ETOH, stored at -20°C
Plasmid prep solution I: 25mM Tris-Cl pH 8.0, 50mM glucose, lOmM EDTA 
Plasmid prep solution II: 0.2N NaOH, 1% SDS
Plasmid prep solution ID: 3M potassium acetate, 11.5% glacial acetic acid 
DNA sample loading bufer: 20% ficoll 400,0.1 M EDTA pH 8.0,1.0% SDS, 0.25% 
Bromophenol Blue, 0.25% Xylene Cyanol 
DNA Standard Molecular Weight Marker: Make a stock solution by adding 10pl of
Lambda BstE-2 Digest (730pg/ml) to 40pl of DNA sample buffer, store at -20 °C.
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Load 3.5|il into a small well for agarose gel electrophoresis 
Protein sample buffer: 62.5mM Tris-Cl pH6.8,12.5% Glycerol, 1.25% SDS, 0.35M 
pME, 0.05% Bromophenol Blue 
10% Polyacrylamide Separating Gel: 12.1ml H20 ,7.5ml of 1.5M Tris pH 8.8,0.3ml of 
10%SDS, 10ml of Acrylamide/Bis acrylamide (30/0.8), 0.1ml 10% APS, and 
7.5JI1 TEMED
3% Polyacrylamide Stacking Gel: 6.3ml H20 ,2.5ml of 0.5M Tris pH6.8,0.1ml of
10%SDS, 1ml of Acrylamide/Bis acrylamide (30%/0.8%), 0.1ml 10% APS, and 
5.0pl TEMED
SDS-PAGE Gel Stain: dissolve 1.25g Coomassie Brilliant Blue in 227ml methanol, add 
46ml glacial acetic acid and 227ml H2O, filter 
SDS-PAGE Gel Running Buffer (10X): combine 60g Tris base, 288g glycine, and 20g 
SDS, add H2O to 2 liters 
SDS-PAGE GelDestain: combine 454ml methanol, 92ml acetic acid, and 454ml H 2O 
500(lM dNTP mix: combine 5010.1 of lOmM dATP, 50 jlQ of lOmM dTTP, 50 (il of 
lOmM dGTP, 50 |il of lOmM dCTP, and 800|il of sterile H2O 
Superose 12 buffer: 100 mM Tris pH 8.5, 50 mM KC1, 5% glycerol, lOmM BME, 1 mM 
EDTA, 0.1% TX-100
TSK buffer for protein purification: 50 mM Tris-Cl pH 7.5, 50 mM KC1,0.1 mM DTT,
0.2 mM EDTA, and 0.1% TX-100 
6% DNA Sequencing Gel: Dissolve 25.2g Urea in 24ml H2O, add 6ml 10X TBE and 
9ml Acrylamide/Bis (38%/2%), 250|il 25% APS, 60(J.l TEMED 
Tryptophan: 1% solution
Fluorescence Buffer: 50mM Tris pH 8.0,50mM KC1, lOmMMgCh, ImM DTT 
Annealing Buffer: 50mM Tris pH 8.4, 80mM KC1, 7mM MgCh, 5mM DTT
20
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Supplies (from Fisher unless otherwise noted)
Glassware includes: beakers, flasks, graduated cylinders, bottles, test tubes (Becton 
Dickinson), pasteur pipettes (Scientific Products)
Sterile plasticware: 15ml conical tubes, 50ml conical tubes, cryovials, petri dishes 
Nonsterile plasticware: l,000(il, 100(J.l, and 10|il pipet tips; 250ml, 50ml, and 15ml
centrifuge bottles and tubes (Nalgene); 1.5ml and 0.5ml microcentrifuge tubes; 
disposable pipets; 1 liter culture flasks;
Stir bars
Cluture loop and glass culture spreader
3ml,10ml, and 60ml syringes (Becton Dickinson)
18 and 20 guage needles (Becton Dickinson)
Eppendorf adjustable pipets: 100-1,OOOfil, 10-100(ll, and 0.5-10|ll 
Quartz cuvettes for DNA measurements 
Quartz cuvettes for fluorimetry
Plastic cuvettes for cell culture and protein measurements 
Tracer Blood Glucose Test Strips (Boehringer Mannheim) 
pH Indicator Paper, Type CF (Whatman)
Dialysis tubing - 30,000 MW 
Tissue culture filter, 250ml (Nalgene)
Sterile Acrodisc, 0.2pM (Gelman Sciences)
YM30 Diaflo ultrafilter membranes 
Centricon-30 microconcentrators (Amicon)
Columns: 500ml, 50ml, 15ml (pharmacia)
Glass beads (Sigma)
Razor blades (VWR Graphics)
EDF film, Kodak (Promega)
Developing trays
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Silver Sequence staining trays 
Nitrogen gas (AIRCO)
Helium, high purity (AIRCO)
Equipment
Autoclave - Market Forge Sterilmatic 
Bead beater - Biospec Products
Centrifuges: Eppendorf Microcentrifuge 5415C kept at 4°C
Savant Speedfuge HSC10AC kept at room temperature 
Beckman Model J 2-21, rotors JA-14 and JA-20 
Beckman L-70 Ultracentrifuge, rotor VTi 65 
Computer Software: CA Cricket Graph III - Computer Associates 
MacVector - IBI, Kodak 
DNA sequencing apparatuses, 21cm x 40cm and 21cm x 50cm - BioRad 
Dry bath, adjustable temp - Fisher 
Econo Pump - BioRad
Electrophoresis Systems, FB 452 and FB 600 - Fisher Biotech 
Fluorescence Spectrophotometer, MPF-44A - Perkin-Elmer 
Fraction collector - BioRad
High Pressure Liquid Chromatograph : BioLC - Dionex 
Integrator, 4400 - Dionex 
Incubator - Fisher 
Microwave - Amana
Mini Horizontal Electrophoresis Apparatus - Sratagene 
Scintillation counter, model LS1701 - Beckman 
SDS-PAGE apparatus, "Mighty Small" - Hoefer Scientific Instruments 
Shaker, Orbit Environ - Lab-Line Instruments, Inc.
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Spectrophotometer, Spectronic 1001 - Bausch & Lomb
Speedvac Concentrator SVC 100H and Refrigerated Condensation Trap - Savant
Stirred Ultrafiltration Cell - Amicon
Superose 12 FPLC column - Pharmacia
Thermocycler, Temp-Tronic - Bamstead/Thermolyne Corp.
Tube Sealer - Beckman
TSK G3000 SW HPLC gel filtration column - TosoHaas 
UV light box: Fotodyne Incorp., Hoefer Scientific Instruments 
Vortex - Fisher 
Water bath - Fisher
23
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METHODS
Yeast Plasmid Expression Vector, pAB24/RT5, and Original Yeast Strain, AB110
The RT gene that was used to produce wild type enzyme originally comes from a 
clone of the viral DNA prepared from a San Francisco isolate of HIV called ARV-2 (35, 
46). The plasmid containing the RT gene, pAB24/RT5 (see Figure 4), was prepared by 
Bathurst (20) by modification of pAB24 /RT4, a plasmid constructed in 1987 by Philip 
Barr and coworkers (26). A 78 base pair synthetic oligonucleotide was ligated onto the 
end of the RT4 gene extending the coding region to Leu715. This made the gene code 
for the full length 66kD monomeric polypeptide (RT5) from Prol56 to Leu715, amino 
acid positions on the HIV pol open reading frame (20, 26). The RT expression cassette 
is flanked by BamH-1 and Sal-1 restriction enzymes so the cassette can be removed and 
manipulated using recombinant DNA technology.
pAB24/RT5 is an autonomously replicating plasmid which is designed to 
constitutively express the RT gene in yeast (20, 26). Saccharomyces cerevisiae strain 
AB110 (Mat a  leu 2 trp 1 ura 3-52 pr Bl-1122 pep 4-3 pr Cl-407 [cir0]) was used to 
express the gene for the wild type RT, RT5 (20). Expression is controlled by the 
glyceraldehyde-3-phosphate dehydrogenase (GAPDH) promoter and terminator which 
flank the RT gene (26). When glucose levels in YPD media containing 1% glucose are 
used up by the yeast cells, the promoter is activated and expression of the RT gene 
begins. Yeast cells containing the plasmid are initially selected for by growing them in 
leucine minus rich media, which contains 8% glucose for 24 hours at 30°C. The plasmid 
contains a gene for leucine so only cells containing plasmids with this gene survive.
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Figure 4. Diagram showing linear and circular plasmid maps of the yeast expression 
vector, pAB24. This plasmid is used for replication and expression of wild type RT5, 
mutant L289R, and mutant L289P. The RT gene is carried in a Sal-l/BamH-1 cassette.
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Once yeast cells containing pAB24/RT5 have been selected by growing in leucine minus 
media they are transferred to 1% glucose YPD media and grown for 30 hours at 30° C to 
induce expression.
New Yeast Strain, XS95-6C
For cloning the mutated enzyme a new yeast strain was used called XS95-6C 
(Mat a rad 52-1 his 3-31 leu2-3 leu2-112 ura3-52 trpl-289a [cir0]). The main difference 
between these yeast cells and the strain used previously is that the new strain is not 
protease deficient so the new strain may produce a protease that will break down the RT 
as it is expressed. The methods used for determining efficiency of protein expression will 
be described later. First, an experiment was done to determine the growth curve for the 
XS95-6C yeast strain. Briefly, an overnight culture from 1 colony is grown in YPD 
medium. The cells are grown until the optical density at 600nm (ODeoo ) is 
approximately 1.0 . Three flasks containing 250ml YPD each are inoculated with the 
overnight culture, one with 500(xl, one with 1ml, and one with 2ml. The cultures are 
incubated on a shaker at 37° C and a 1ml sample is removed from each culture 
approximately every 4 hours and the OD600 recorded.
Isolation of pAB24/RT5 from Yeast
Plasmid carrying the gene for wild type RT (RT5) must be isolated from the yeast 
strain AB110 so it can be used as template for PCR mutagenesis. This procedure is based 
on a method from Current Protocols in Molecular Biology (48). First grow an overnight 
culture by inoculating 3 mis of leucine-minus, rich media with 1ml stock culture. 
Incubate 24 hrs at 30° C on shaker. Put 1.5 mis of yeast culture into each of 2 
microcentrifuge tubes. Pellet cells by centrifugation for 5 seconds at top speed, room 
temperature. Discard supernatant and resuspend cells in 200(0.1 of breaking buffer. Add 
200|il glass beads and 200|ll phenol/chloroform/isoamyl alcohol (25:24:1). Vortex
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highest speed for 2 minutes. Centrifuge 5 minutes, room temperature. Transfer the top 
layer to a fresh tube and ethanol precipitate the DNA.
Ethanol Precipitation of DNA
Ethanol precipitate the aqueous DNA solution with 2 parts 100% EtOH to 1 part 
aqueous sample plus 1/10 of the DNA sample volume of 3M sodium acetate solution pH 
5.2. Store at least 2 hours at -20°C. Centrifuge 20 minutes at 4°C, top speed. Wash 
pellet with 70% EtOH and dry in Speed Vac. Resuspend plasmid DNA pellet in TE 
buffer.
Prepare competent E. coli
Inoculate 100 ml of LB broth in a 500 ml flask with 1 ml of an overnight culture 
of HB101 cells. Grow cells with vigorous shaking at 37 °C to a density of approximately 
5xl07 cells/ml (0.5 OD550), usually about 2 to 4 hours. Use 3 mis for each 
transformation. Chill on ice for 10 minutes. Spin at 4,000g for 5 min at 4°C. Discard 
supernatant. Resuspend cells in half the original culture volume (if starting with 3 mis 
use 1.5mls) of ice-cold, sterile solution of 50 mM CaCl2 and lOmM Tris-Cl, pH 8.0. 
Place in ice bath for 15 minutes and spin 5 minutes at 4°C. Discard supernatant. 
Resuspend cells in 1/15 of the original volume ( if started with 3 mis use 200|ils) of ice- 
cold, sterile solution of 50 mM CaCU and lOmM Tris-Cl, pH 8.0. Dispense 200 (il 
aliquots into prechilled tubes. Store cells at 4°C for 12-24 hours before transformation or 
at -70 °C indefinitely.
Transformation of HB101E. coli with pAB24/RT5 from Yeast
The transformation of E. coli with plasmid is based on a procedure from the 
Maniatis laboratory manual (49). Add up to 40ng of DNA (dissolved in up to lOOjols of 
TE buffer) to each tube of competent cells. Mix and incubate on ice 30 minutes.
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Incubate at 42°C for 2 minutes then put back on ice. Add 1 ml LB broth (without 
ampicillin) and incubate 37 °C for 1 hour without shaking. Set up dilutions and place 
100|il of each dilution (plus 1 undiluted) on LB + ampicillin plates and spread evenly 
over entire plate.
Set up control plate using untransformed cells with no DNA added. Incubate 12- 
18 hours at 37 °C, no longer, then store at 4°C. Make stock cultures of any colonies that 
grow and do plasmid miniprep on one of the stocks to do restriction mapping of the 
plasmid to confirm that pAB24/RT5 is present in the HB101 cells .
Stock Culture Preparation
Place 1 colony of transformed E. coli in 5 ml LB + ampicillin media. Incubate 
37°C overnight on shaker. Add 5 ml 30% sterile glycerol for a final concentration of 15% 
glycerol. Place 250|il aliquots into cryovials and store at -70°C.
Miniprep of Transformed E. coli, Alkaline Lysis Method
The following procedure is based on the method described in the Maniatis lab 
manual (50). Take one of the above stock cultures and place in 5ml LB media with 
ampicillin. Incubate 37° C overnight on shaker. Put 1.5ml of the overnight culture in a 
microfuge tube and spin 1 minute to pellet cells. Store rest of culture at 4°C for up to 1 
week. Discard supernatant. Resuspend pellet in lOOpl of ice cold Solution I. Incubate 5 
minutes, room temp, uncapped. Add 200|E fresh Solution II and invert rapidly 2-3 times 
(don’t vortex). Incubate on ice 5 minutes. Add 150|il of ice cold Solution El and vortex 
gently while inverted. Incubate on ice 5 minutes. Centrifuge 5 minutes at 4°C. Transfer 
supernatant to a fresh tube. To purify the DNA first add an equal volume of Tris- 
buffered phenol pH 8.0. Mix by vortexing 5 minutes and then centrifuge at highest speed 
for 10 minutes at room temperature. Transfer the top aqueous layer to a fresh tube and 
add an equal volume of phenol/chloroform/isoamyl alcohol (25:24:1). Mix and spin as
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above and transfer the top layer to a fresh tube. Add an equal volume of chloroform / 
isoamyl alcohol (24:1) and mix, centrifuge, and transfer top layer to fresh tube as above. 
EtOH precipitate the aqueous DNA sample as described above. Resuspend dry pellet in 
TE buffer which contains DNase-free pancreatic RNase (20pg/ml).
Quantitate DNA
Zero spectrophotometer with 1 ml of water or TE buffer, whichever the sample is 
in, at 260nm in glass cuvette. Record absorbance of the blank at 280nm. Add 1 pi of 
DNA sample and record absorbance at 260nm and at 280nm. Determine purity as 
follows: divided the absorbance at 260nm by the absorbance at 280nm. Determine the 
concentration as follows: absorbance at 260nm multiplied by 50pg/l OD for double­
stranded DNA, or 40pg for single-stranded DNA and RNA equals the concentration in 
pg/pl (51).
Restriction Enzyme Analysis of Plasmid
In order to confirm that I have obtained the correct plasmid from the transformed 
E. coli , the DNA is digested with restriction enzymes which will cut the DNA in 
specific places. The sample is then run on a 1 % agarose gel and stained with ethidium 
bromide. The result will be a specific pattern of bands of different sizes. For digestions 
use 1-5 U of restriction enzyme per (Jig of DNA . BamH-1 is 16U/pl, Sal-1 is 8U/pl, 
and Hind-3 is lOU/pl.
1. BamH-1 + Sal-1 Digest
Combine up to lOpg Plasmid DNA in 7pi sterileTE or H2O, plus 1.0 pi 10X 
Buffer D, 1.0 pi BamH-1, and 1.0 pi Sal-1, in a 1.5ml microcentrifuge tube. Incubate 2 
to 3 hours 37°C . Add 1.0 pi lOx DNA sample buffer and run on 1% agarose gel im­
mediately or store at -20°C. Digest results in 2 fragments: 1) 2,096 bp and 2) 13,965 bp.
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2. Hind-3 Digest
Combine up to 10|iig Plasmid DNA in 7jll sterileTE or H2O, plus l.Opl 10X 
Buffer B, l.Opl Hind-3, and 1.0 p.1 H 2O, in a 1.5ml microcentrifuge tube. Incubate 2-3 
hours 37 °C . Add l.Opl lOx DNA sample buffer. Run on 1% agarose gel immediately or 
store at -20°C. Digest should result in 6 fragments: 1) 1,166 bp, 2) 2,107 bp, 3) 4,285 bp, 
4) 3,430 bp, 5) 1,314 bp, 6) 2,659 bp.
1 % Agarose Gel Electrophoresis
l.Og low gelling temperature agarose is dissolved in 100ml TAE buffer by 
heating in a microwave. The solution is allowed to cool slightly and poured into a 
Stratagene gel casting apparatus. Once the gel solution has hardened the gel is covered 
with TAE buffer, the dams and comb removed, and DNA samples which have been 
mixed with DNA sample loading buffer/tracking dye are loaded into wells. Lambda 
DNA BstE 13 Digest is used as a size marker. The gel is run at 100 volts or less. The gel 
is stained in ethidium bromide solution (0.5|ig/ml final concentration) for 10 minutes and 
then rinsed in dH20  for 30 minutes. Using a UV light box to illuminate the stain, a 
photograph can be taken to record the image and, if desired, bands can be cut out of the 
gel and purified for later manipulation.
PCR Mutagenesis
Site-directed mutagenesis, also called site-specific mutagenesis or oligonucleotide 
directed mutagenesis will be used to correlate specific changes in the DNA sequence with 
effects on function of RT. There are many different methods of site-directed mutagenesis 
which can be used to change a single amino acid of a cloned protein (52). One of the 
newest mutagenesis methods uses the polymerase chain reaction (PCR) which is very 
quick, simple, and efficient compared to traditional methods. The first use of PCR to 
amplify DNA was in 1985 (53). It was immediately realized that PCR could be used to
30
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
engineer DNA in many different ways (54, 55, 56). For example, PCR could be used to 
introduce restriction sites (54), to make base substitutions (57, 58), to make insertions or 
deletions (59), or to assemble overlapping oligonucleotides into long synthetic DNA 
fragments (60). Since our lab is equipped with a thermocycler which is necessary for 
PCR procedures, this method of mutagenesis is the most practical for our lab to use. A 
drawback of PCR mutagenesis has been that it used Taq polymerase which does not 
possess 3’ to 5’ exonuclease activity and, consequently, cannot correct misincorporation. 
The error rate of Taq polymerase is estimated to be about one error every 900 bases (61, 
62). Recently, a new PCR polymerase enzyme has been put on the market by Stratagene 
called Pfu polymerase which does have proofreading ability and, according to the 
manufacturer, shows a twelve fold increase in fidelity over Taq . I have designed a 
procedure for creating a base pair substitution at amino acid position L289 of HIV-1 RT 
using PCR mutagenesis. The outline for this procedure is shown in Figure 5.
PCR mutagenesis requires four synthetic oligonucleotide primers designed to bind 
specific strands of template DNA at strategic sites. Primer binding sites depend on where 
unique restriction sites are in the RT gene and where the desired sequence change is 
located. As can be seen in Figure 5 the outside primers, PI and P6, are designed to be 
adjacent to AlwN-1 and Sal-1 restriction sites of the RT gene so that the PCR 
mutagenesis product can be cut and inserted into the plasmid vector. The inside 
overlapping mutagenic primers, P2 and P3 for mutant#! or P4 and P5 for mutant#2, are 
complimentary to each other at the 5’ end but mismatch the template at the site of the 
desired base change. The design of the oligonucleotide primers is critical to successful 
PCR mutagenesis and must be chosen carefully. They should be at least 20 base pairs in 
length or have a GC content of 50% or greater, and the overlapping region between the 
two inside primers should be at least 20 base pairs . The 6 primers used for creating the 
two mutants are shown in Figure 6. The RT DNA and amino acid sequences are shown 
in Figure 7 along with primer binding sites and restriction enzyme sites.
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Figure 5. Diagram showing the procedure for using the polymerase chain reaction (PCR) 
to create a site-specific mutation in the RT gene.
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Figure 6. Primers used for making two RT mutants using PCR mutagenesis.
Primers 1 and 6 are the outside primers used for both mutations. Primers 2 and 3 are the 
inside mutagenic primers for creating the L289P mutation. Primers 4 and 5 are the inside 
mutagenic primers for creating the L289R mutation.
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PCR Primers %GC
Primer# 1: 5' GAGGAACTGAGACAGC 3’ (16) 56
Primer # 2: 5’GGTATTACTTCTGTTGGTGCTTTGG 3' (25) 44
Primer # 3: 5' GCACCAACAGAAGTAATACC 3’ (20) 45
Primer # 4: 5' GGTATTACTTCTGTTCGTGCTTTGG 3' (25) 44
Primer #5: 5’ GCACGAACAGAAGTAATACC 3' (20) 45
Primer # 6: 5' GTCGACTATAGTACTTTCCT 3’ (20) 40
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Figure 7. DNA and amino acid sequence of the RT gene. The sites for PCR primer 
binding are shown as well as the restriction enzyme sites used to place the mutated 
fragment into the plasmid expression vector.
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The exact concentrations of ingredients for the PCR reaction mixtures was deter­
mined through experimentation. Generally, the 100|il reaction mixture contained: 2.5 U 
Pfu DNA polymerase, 1|J.M of each primer, 0.1 to 250ng template DNA, 300(lM of each 
dNTP, and 10|ll of lOx pfu buffer. DNA template samples that contain EDTA, such as 
TE buffer, should use a lOx pfu buffer that contains 20mM Mg2Cl. The cycle condi­
tions depend on the DNA template, the DNA primer, and the desired product.
Amplification of fragments A and B
Turn on thermocycler 1/2 hour before using, and program it as follows: dwell at 
95°C for 10 minutes, denature at 95°C for 5 minutes, anneal at 55°C for 5 minutes, 
extend at 72°C for 5 minutes, dwell at 4°C. Set up the following reaction mixes:
For fragment A (265 bpl: For fragments BC829 bp):
24(il sterile, dd t^O  24pl sterile, ddE^O
10(xl 10X pfu buffer #1 10(il 10X pfu buffer #1
60|il dNTP mix 60(ll dNTP mix
130ng plasmid, pAB24/RT5 130ng plasmid, pAB24/RT5
2(0.1 of 50(tM Primer #1 2(il of 50|iM Primer #3
2(0.1 of 50(lM Primer #2 2|0l of 50(lM Primer #6
Set up a negative control as above except without DNA template. Put 1 AmpliWax PCR 
Gem 100 pellet into each tube. Begin program described above on thermocycler. After 
an initial 10 minute dwell, add l|0l pfu polymerase to each tube and resume program for 
30 cycles. Once the program has finished add 10(11 of lOx DNA sample buffer to each 
tube and store at -20°C.
Isolate and Purify Fragments A and B
Run PCR reaction mixture along with DNA size markers on a 1% agarose gel. 
Using a UV light box to illuminate the stain, cut out desired bands with a razor blade and
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place in 1.5ml microcentrifuge tubes. Each tube should contain about 100 (il of agarose 
containing D NA. Add 400(0.1 of TE buffer to each tube and heat to 65° C to melt agarose. 
Add 500|ol of phenol and vortex at low speed for 5 minutes. Centrifuge at top speed for 
10 minutes to separate layers. Collect top aqueous layer and re-extract with phenol. Add 
500|J.l of TE buffer to bottom phenol layer and re-extract. Combine aqueous layers and 
ethanol precipitate as described above. Resuspend pellet in TE buffer and quantitate 
DNA as described above.
Synthesis of Mutant Fragment C
First, create a linking program on the thermocycler made by linking two different 
programs together. The first program is designed to enhance annealing of the two 
fragments A and B which have 20 complimentary base pairs at their 5-prime end (+ 
strand). When the two fragments are combined in the PCR reaction mixture with primers 
and then denatured, there are six possible recombinations which are shown in Figure 8
Extension of annealing product #6 will result in the new 1,084 bp fragment C.
The first part of the two part program is as follows: Dwell at 95°C for 10 minutes, 
denature at 95°C for 1 minute, anneal at 45°C for 4 min, and extend at 72°C for 2.5 
minutes, for 4 cycles. Link this program to the following program: denature at 95°C for 
1 minute, anneal at 50°C for 2 minutes, and extend at 72°C for 2.5 minutes, for 25 
cycles. Dwell at 4°C until morning. Fragment C is isolated from the PCR mixture as 
described above for fragments A and B and digested with AlwN-1 and Sal-1 as described 
below.
AlwN-1 + Sal-1 Digest
To 8p.l of fragment C DNA in TE buffer add l[il of AlwN-1 enzyme and 1(0.1 of 
Promega Buffer E in a 1.5ml microcentrifuge tube. Incubate 2 hours then add 2.5(il of 
H20 , 1.5(01 of Promega Buffer D, and lp.1 of Sal-1 enzyme and incubate for 2 more hours.
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Figure 8. Diagram showing the six possible fragments produced during the formation of 
fragment C in PCR mutagenesis. Extension of #6 will result in a double stranded DNA 
fragment containing the desired mutation.
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Add 2|il of DNA sample buffer and run on a 1% agarose gel. Isolate and purify the 
fragment from the gel as described above.
Method for Putting Mutant Fragment C into Expression Vector
The procedure for placing the mutated fragment C back into the yeast expression 
vector, pAB24, is summarized in Figure 9. The first step of digesting plasmid pAB24 
/RT5 with BamHl and Sal-1 restriction enzymes was described above. The digest is run 
on a 1% agarose gel and the large and small BamH-l/Sal-1 fragments isolated and 
purified from the gel. The large fragment is stored at -20° C for later use. The small 
fragment is digested with AlwN-1 and Pvu-2 as described below. The Pvu-2 digest 
serves to divide the AlwN-1/Sal-1 fragment into smaller pieces so that it will not be 
confused with the BamH-l/AlwN-1 fragment which is the same size. This makes 
isolation of the BamH-l/AlwN-1 fragment in 1% agarose gel easier (see Figure 9). 
Combine 10[il of the small BamH-1/ Sal-1 fragment (l|ig/|il), 1.5(11 H2O, 1.5(j.l 10 x 
Promega Buffer C, l|J.l AlwN-1, and l(_ll Pvu-2 and incubate at 37° C for 2 hours. Run 
this digest mixture on a 1% agarose gel to separate the fragments by size as follows: 
BamH-l/Sal-1 (2,090), BamH-l/AlwN-1 (l,025bp), AlwN-l/Pvu-2 (135bp), Pvu-2/Sal-l 
(830bp). Isolate and purify the BamH-l/AlwN-1 fragment as described above and 
resuspend in TE buffer. Ligate the BamH-l/AlwN-1 fragment with the PCR mutated 
AlwN-l/Sal-1 fragment as follows: Combine 2.5(ll H2O, 5p.l (2pmol) of the AlwN-l/Sal- 
1 fragment (0.3p.g/pl), 5|il (14.8pmol) of the BamH-l/AlwN-1 fragment (2.0[lg/|ll), 1.5|il 
ligase buffer, and 1.0|il ligase and incubate at 4°C for 48 hours. Add lp.1 (lpmol) of the 
BamH-l/Sal-1 fragment (1 l|ig/p.l) and incubate another 48 hours. Set up several trans­
formation reactions using different dilutions of the ligation mixture and 200|il of 
competent HB101 E. coli cells per 1.5ml tube (see procedure described above). 
Transformation mixtures are plated on LB+ ampicillin plates and incubated at 37°C. E. 
coli that grow on the selective plates contain the mutated RT plasmid vector.
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Figure 9. Diagram showing how the PCR mutated fragment was inserted into the yeast 
expression vector, pAB24. The original plasmid vector carrying the gene for wild type 
RT, pAB24/RT5, was digested with restriction enzymes in order to remove the fragment 
corresponding to the PCR mutated fragment which has been digested with AlwN-1 and 
Sal-1. Ligating the desired digestion products together results in the formation of a new 
plasmid containing the site-specific mutation, pAB24/RT5M.
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MaxiPrep of mutant pAB24/RT5 from Transformed E.coli
To obtain large amounts of plasmid for sequencing and transformation into yeast, 
a large scale preparation using cesium chloride gradient ultracentrifugation was used. 
Grow up a liter of E. coli cells containing the mutated plasmid in LB + ampicillin 
medium. Harvest the cells by centrifugation at 4,000 x g (6, 000 rpm) in 250ml 
centrifuge bottles in JA-14 rotor at 4°C for 10 minutes. Discard supernatant and 
resuspend each pellet (from 250mls of culture) in 5ml ice cold Solution I and incubate 
uncapped 5 minutes at room temperature. Add 10ml fresh Solution II close top, invert 
rapidly 2-3 times, and store on ice 5 minutes. Add 7.5ml ice cold Solution III close top 
and vortex inverted 10 seconds. Store on ice 5 minutes. Centrifuge 15,000rpm in JA-20 
rotor 15 minutes at 4°C and transfer supematnat to a clean tube. Spin again at 
15,000rpm for 10 minutes and transfer supernatant to a clean tube. Add 10ml phenol, 
mix, centrifuge 3,000rpm for 10 minutes and transfer aqueous (top) layer to a clean tube. 
Add 9.45ml isopropanol, mix, let stand 5 minutes at room temperature then spin 12,000 
rpm for 10 minutes. Discard supernatant and wash pellet with 70% EtOH. Dry pellet 
and resuspend in TE buffer. Run sample on 1% agarose gel to see if plasmid is present. 
Set up the cesium chloride gradient using two DNA samples or one sample and a buffer 
blank to use as a balance. Put DNA sample in a tube and add H2O so final volume is 
4.1ml. In a 50ml tube add 4.2g cesium chloride and the DNA solution. Mix, add 150|il 
of stock ethidium bromide solution and mix again avoiding bubbles. Take the plunger 
out of a 3ml syringe, put on an 18 gauge needle, and place the needle of the syringe into 
the opening of an ultracentrifuge tube. Pour the DNA-cesium chloride mixture into the 
syringe so it fills up the ultracentrifuge tube without any bubbles. Balance tubes to 
within 0.05g. Seal tubes and place in ultracentrifuge rotor according to manufacturers 
instructions. Samples are spun overnight at 55,000 rpm and 22°C. DNA is visualized 
using a UV light and removed using a needle and syringe after first making an air hole in 
the top of the centrifuge tube with the needle. The DNA is separated from ethidium
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bromide by extracting repeatedly with a 5M NaCl saturated N-butanol solution. Once the 
bottom aqueous layer containing the DNA is no longer pink, the DNA is precipitated 
by adding 2 volumes of H 2O, 6 volumes of 100% EtOH, and 1/20 volume 3M sodium 
acetate, pH 5.2. Run the DNA sample on a 1% agarose gel to determine if RNA is 
present. If RNA is present then the sample must be treated with RNase and the phenol 
extraction and ethanol precipitation procedures repeated to remove the RNase. The RNA 
can also be removed using GeneClean according to the manufactures instructions.
DNA Sequencing
There are several methods for direct sequencing of PCR products which use 
different ways of generating single-stranded DNA for sequencing (64, 65, 66). After first 
trying USB's Sequenase kit and Promega's Fmol kit it was found that Promega's Silver 
Sequence method, which uses asymmetric PCR amplification of the DNA template, was 
the most successful. The Silver Sequence method detects bands in a DNA sequencing gel 
using a sensitive silver staining procedure and does not require the use of any radioactive 
materials. The stained bands can be observed with the naked eye but reading and 
recording of the sequence is aided by placing the stained gel on top of a fluorescent light 
box. The overall sequencing reaction is based on Sanger's enzymatic dideoxy sequencing 
method (67, 68) which requires single-stranded template DNA. A variation of Sanger's 
enzymatic sequencing method uses thermocycling and thermostable taq DNA polym­
erase which allows the use of double-stranded DNA as template. Thermocycling also 
improves specificity of primer hybridization and decreases formation of secondary 
structures of the DNA template (69).
The first step of any sequencing method is to obtain very clean DNA which was 
done using the maxiprep method described above. For Silver sequencing 2pmol or 22(ig 
of plasmid DNA was used . By following the manufacture's instructions and using high 
purity H 2O and sodium carbonate, and by not rinsing too long after the staining
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procedure, the method was usually successful. Briefly, for each sequencing reaction set
up four 0.5ml tubes labeled A,C,G, and T and pipette 2|il of each ddNTP mix into the
appropriately labeled tube. Add one drop of oil to each tube then place tubes on ice. In a
separate tube combine 6.5pl sterile H2O, 5.0pl 5x sequencing buffer, 4.0fil DNA
(5.25(lg/|ll), and 0.5|ll1 of 50|iM primer. The same primers that were used for PCR
mutagenesis were used for DNA sequencing. 1(0.1 of Taq DNA polymerase was added to
the sequencing reaction mix which brings the total volume to 16 p.1. Pipet 4|il of this
mixture into each of the 4 ddNTP tubes. Spin the tubes briefly and place in the
thermocycler preheated to 95°C which has been programmed as follows:
Dwell at 95 °C for 2 minutes, then 
Step 1:95 °C for 0 seconds 
Step 2:95 °C for 30 seconds (denaturation)
Step 3 :42°C for 0 seconds
Step 4:42 °C for 30 seconds (annealling)
Step 5 :70°C for 0 seconds 
Step 6 :70°C for 30 seconds (extension) 
for 60 cycles.
Samples can be kept in thermocycler dwelling at 4°C for overnight if desired. Add 3|il of 
stop solution to each tube and store on ice or at -20°C. Heat samples at 70°C for 2 
minutes before loading onto a 6% polyacrylamide gel containing 8M urea. For silver 
staining the sequencing gel the plates must be specially prepared. The short plate is made 
sticky using a binding solution prepared with Bind Silane which comes with the kit. The 
long plate is made slippery with either Sigmacote or Rainex, bought separately and used 
according to manufacturer's instructions. Care is taken to make sure plates are extremely 
clean before preparing and not to cross-contaminate plates by changing gloves as the kit 
suggests. The gel rig is assembled and the gel poured according to manufacture's 
directions, except the bottom is sealed differently. A spacer is cut to fit across the 
bottom in between the two side spacers and, unlike the side spacers, is coated with 
silicon grease to insure that no leakage occurs through the bottom while pouring the gel.
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60mls of a 6% acrylamide gel solution is made as described in the Materials section. 
lOmls of this solution was set aside and to the remaining 50mls add 170(ll of a 25% 
ammonium persulfate (APS), and 45|ri of TEMED to catalyze polymerization. After the 
main part of the gel has polymerized the bottom spacer is removed. 42p.l of 25% APS 
and 10|tl of TEMED is added to the lOmls of acrylamide solution previously set aside 
and the solution is poured in to fill the space at the bottom of the gel. Originally, a 
square toothed 16 well comb was used, but this was replaced with a 24 well sharks 
toothed comb which results in lanes that are much closer together and thus easier to read. 
Two different size apparatuses were used for sequencing, spacer thickness for both was 
4mm. The first apparatus was 21cm x 40cm and was run at 1800volts, 55watts, and 
35mAmps. The second apparatus was 21cm x 50cm and was run at 2000volts, 60watts, 
and 35mAmps. The temperature was closely observed and settings adjusted when 
necessary to maintain a running temperature of 50° C. Gels were pre-run until the 
temperature reached at least 45 °C before loading samples . The length of time for each 
run depended on which region of the sequence was being read. A maximum of 200 bases 
could be read on the shorter apparatus after running the gel 4 hours. The longer gel was 
run 4 to 8 hours and up to 350 bases could be read. Gels were stained according to 
Promega's Silver Sequence instruction manual and the image recorded as follows. In a 
dark room place the gel attached to the glass plate on top of a fluorescent light box 
turned off. Place a piece of Kodak EDF film on top of gel, turn light box on for 1-2 
seconds and turn off. Place film in developer solution for 2 minutes, rinse in water for 1 
minute, place in fixative for 3-5 minutes, then rinse in water and hang to dry.
Yeast Transformation
The spheroplast method of yeast transformation (70) was used to place mutated 
pAB24/RT5 into yeast strain XS95 for expression and purification of mutant enzymes, 
L289R and L289P. This method uses the enzyme p-glucuronidase to remove the cell wall
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from the yeast cells, making them spheroplasts, so that DNA can pass through the cell 
membrane. The procedure can be divided into two parts, 1) the formation of sphero­
plasts, and 2) the transformation of spheroplasts. First sterilize the following glass/plastic 
ware: (1) 10-15ml test tube for growing the overnight culture, (4) 250ml flasks, (4) 
50ml round bottom centrifuge tubes, (1) 50ml flask, (6) 10ml glass test tubes. Prepare 
the following solutions as described in the Materials section: 1M sorbitol, CaCl2 solution, 
sorbitol/CaCh solution , filter sterilized PEG/CaCl2 solution, and p-Glucuron-idase 
(90,000 U/ml). Prepare at least 200mls YPD liquid medium and 2 YPD plates. Prepare 
500mls leucine minus selective regeneration agar. Prepare 500mls leucine minus 
medium for selective plates. To prepare spheroplasts, first grow an overnight culture by 
inoculating 2mls of YPD with 1 colony of the XS95 yeast and grow overnight at 30°C on 
a shaker. The next day use different amounts of this culture to inoculate 4 different 
250ml flasks containing 50mls of YPD as follows: 1) 100(0.1, 2) 250(il, 3) 500|il, and 4) 
lml of overnight culture. Grow until OD goo of one of the cultures reaches 0.5, about 18 
hours. The next day melt the selective regeneration agar and aliquot lOmls into each of 6 
sterile test tubes and place in 55°C water bath. Take the culture which has an ODeoo that 
is closest to 0.5 and pellet in 50ml sterile centrifuge tube by spinning at 1100 x g (3500 
rpm) 5minutes, room temperature in JA-20 rotor. Discard supernatant and resuspend 
pellet in 10ml 1M sorbitol. Repeat this step. Pellet cells again and resuspend in 5mls of 
1M sorbitol. Take l(il of this cell suspension and make a 10-5 dilution in sterile H2O. 
Plate 100(tl of this dilution on a YPD plate and incubate 2 days at 30°C. This plate will 
indicate cell viability before p -Glucuronidase treatment. Put yeast cell/sorbitol 
suspension in a 50ml sterile flask and add 5(0.1 of p-mercaptoethanol and 150(tl of p- 
Glucuronidase (13,500 U). Incubate 60 minutes at 30° C with very gentle shaking. Take 
1(0.1 of this cell suspension and make a 10‘3 dilution in sterile H2O and plate 100(0.1 on a 
YPD plate and incubate 2 days at 30°C. If spheroplasts are present they will lyse in H 2O 
and will not grow on the plate. Calculate % of cells that did not form spheroplasts as
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follows: number of colonies after p-Glucuronidase treatment divided by number of 
colonies before p-Glucuronidase treatment. Transfer the p-Glucuronidase treated cell 
mixture to a sterile 50ml round bottom centrifuge tube and pellet by spinning 4 minutes at 
400 x g. Gently decant supernatant without dislodging pellet. Add 2ml of 1M sorbitol 
and resuspend by gently swirling. Add 8mls of 1M sorbitol and pellet at 400 x g. Decant 
supernatant, add 2mls of 1M sorbitol and resuspend by swirling. Add 8mls of 1M 
sorbitol and pellet by spinning 4 minutes at 400 x g. Decant supernatant, add 2mls of 
1M sorbitol and resuspend by gently swirling. Add 7mls of 1M sorbitol and 1ml of the 
CaCl2 solution. Mix gently by swirling and centrifuge 4 minutes at 400 x g. Decant 
supernatant and resuspend the pellet in 1ml of the sorbitol/CaCl2 solution. Set up 6 
sterile microcentrifuge tubes and place 150|J.l of yeast spheroplasts into each tube. Add 
varying amounts of DNA, up to 10(i.g in <_ 20|ll TE buffer as follows: tube#l) 0|ig 
DNA, tube#2) 0.5|4.g DNA, tube#3) l|!g DNA, tube#4) 2(ig DNA, tube#5) 5(ig DNA, 
tube#6) 10|_lg DNA. Mix DNA with cells and incubate 10 minutes at room temperature. 
Add 1.5mls of PEG/CaCl2 solution thoroughly resuspend and let sit 10 minutes at room 
temperature. Pellet cells, 4 minutes at 400 x g and decant off PEG/CaCh solution. 
Gently resuspend pellet in 0.5ml sorbitol/CaCl2 solution and pipet into lOmls of the 
melted regeneration agar which should be at 55 °C. Vortex briefly and immediately pour 
onto the leucine minus selective plates and swirl to further mix. Incubate at 30 °C until 
colonies appear. Make overnight cultures from single colonies picked from selective 
plates, and make glycerol stock cultures from the overnight cultures for further analysis.
Yeast Expression Experiment
The plasmid containing the mutated gene, pAB24/RT5M, is exactly the same as 
the plasmid containing the wild type gene, pAB24/RT5 except for a single base pair 
substitution in the subunit binding domain of the RT gene. Once the mutated gene was 
constructed, placed back into the plasmid expression vector, and transformed into the
45
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
new yeast strain, the best conditions for growing the new yeast strain and expression of 
the mutated gene were determined by experimentation. Briefly, 250 mis YPD medium 
in a 1 liter flask was inoculated with 25mls of the new yeast strain XS95 (transformed 
with pAB24/RT5M, grown in leucine minus medium) and incubated at 30°C on the 
shaker. 1.5ml aliquots of the culture were taken every hour for 24 hours and the 
following analyses done on each sample: the optical density read at 600nm wavelength, 
the glucose level measured, the pH measured, and the sample stored at -20° C to be 
analyzed later for RT activity and protein concentration. Mini-protein preps were carried 
out on the 26 samples using a glass bead disruption method (71) described below.
Mini-multiple Protein Preps
Each 1.5ml sample was spun 5 minutes at 4°C and the packed cell volume was 
determined to be approximately lOp.1. Cells were resuspended in 30|il of H2O, 
centrifuged, and the supernatant was removed. The cells were then resuspended in 30|J.l 
of disruption buffer plus 40|il of glass beads. The cell mixture was vortexed 1 minute at 
4°C and stored on ice for 2 minutes. This was repeated 3 times. The cell mixture was 
centrifuged 5 minutes at 4°C and the supernatant collected. 200|il of disruption buffer 
was added, the mixture was spun again and the supernatant collected and combined with 
the first supernatant. Each sample was tested for RT activity and protein concentration as 
described below.
Large Scale Protein Isolation and Purification
Procedures for isolation and purification of the RT enzyme described below are 
the same for wild type and mutant RT.
Harvest and Lyse cells
Collect the cell pellets from several 1 liter yeast cultures by centrifuging the
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culture at 10,000 rpm for 20 minutes at 4°C. If pellets have been frozen, place them in a 
large beaker and add enough RT lysis buffer to cover the cell pellets and wait until pellets 
thaw. Put mixture in the bead beater cylinder, add an equal volume of glass beads, and 
add buffer to the top so there is no air in the container. Beat mixture for 15 seconds, let 
cool for 1 minute, and repeat until total bead beating time on is 5 minutes. Pour solution 
into centrifuge bottles and spin at 10,000 rpm for 30 minutes at 4°C. Pour supernatant 
into large beaker. Add more lysis buffer to centrifuge bottles containing glass beads, 
swirl around to wash beads, and centrifuge again. Combine the two supernatants, record 
volume, and remove a 500|J.l aliquot of the crude extract to be analyzed later for activity 
and protein concentration.
Protein Precipitation
Put the beaker containing the cell extract inside another beaker packed with ice. 
Add 39.8g of ammonium sulfate for every 100ml of crude extract - adding it slowly while 
stirring the solution to precipitate out the protein. Centrifuge the solution at 10,000 rpm 
for 20 minutes at 4°C. Discard the supernatant and resuspend the pellet in 10 mis or less 
of RT buffer. Put the precipitated protein solution into sterile 30,000 MW cut off dialysis 
tubing. Dialyze overnight, changing buffer once, against 2 liters of lx RT buffer to 
remove salt. After dialysis, dilute the protein solution 1:1 with RT buffer, remove a 
500|Jl aliquot for later testing.
Ion Exchange Column
Whatman PI 1 cellulose phosphate is a cation exchanger with an ester-linked 
phosphate functional group which will bind or release the RT depending on the salt 
concentration of the running buffer. The phosphorylated cellulose was prepared by first 
washing with 0.5M NaOH and then 0.5M HC1 and resuspending in lOx Tris buffer pH 
7.5. A 500ml column is used for large preps but a smaller 50ml column was used for the
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mutant purifications. The cellulose solution was packed into the columns and 
equilibrated with RT buffer at 4°C. After loading the sample, the column was washed 
with one bed volume of RT buffer. Save the "load" and "wash" eluants for testing. 
Prepare a salt gradient of 50 to 800mM KC1 in RT buffer, 400mls each. RT5 elutes 
between 300 and 400mM KC1. Collect fractions using a BioRad fraction collector set for 
25 minutes/tube while running the gradient. The BioRad Econo Pump is set at 20mls per 
hour. Assay the fractions for RT activity and protein concentration (see below) along 
with crude extract, "load" sample and "wash" sample to determine which fractions 
contain enzyme and what is the efficiency of purification. The results are plotted using 
Cricket Graph HI on a double y axis graph showing protein concentration and absorbance 
versus fraction number. Peak fractions containing the most RT are pooled, concentrated, 
and loaded onto an Affi-Gel Blue column.
Comparison of Ion Exchange Column Purifications
To determine if the mutant purification results from the P l l  column were 
significantly different from wild type purification, the above procedure was repeated 
three times for each mutant including enzyme activity analyses and protein concentration 
determinations. The results were averaged, graphed, and the salt concentrations that 
each mutant eluted at were determined and compared with results of wild type RT5 
obtained previously.
Affi-Gel Blue Column
Affi-Gel Blue affinity gel is a crosslinked agarose bead with Cibacron blue F3GA 
dye covalently bound to it. The dye probably has an affinity for the nucleotide binding 
sight of RT. The gel comes as a wet suspension which is stored and used at 4°C. The 
gel was packed into a 1.5cm x 10cm column and equilibrated with running buffer which 
is RT buffer without KC1. The column, which has a 15ml bed volume, can be loaded
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with lmg to 3mgs of protein per ml of Affi-Gel Blue so that a maximum of 45mg of 
protein could be loaded at a time. The protein solution was loaded and washed with no 
salt RT buffer until the optical density (O.D.) at 280nm of the eluant was consistent. 
Once protein has been loaded onto the column, RT is separated from other proteins by 
elution with a 0-600mM KC1 in RT buffer gradient. Fractions were collected and 
assayed for RT activity and protein concentration.
Superose 12 Column
Further purification is obtained by loading the RT sample onto a Superose 12
FPLC gel filtration column at room temperature. Column settings are as follows: AUFS
= 0.5, flow rate = 0.2ml/min, and high pressure limit = 430psi. Dionex integrator
settings are as follows: peak threshold (PT) = 400,000, chart speed (CS) = 0.1,
Attenuation (AT) = 1024. The integrator was programmed as follows:
TT(1)= 0.01 TF(1)= "T4" TV(1)= 1 (zero detector - on)
TT(2)= 0.01 TF(2)= "T6" TV(2)= 1 (start program)
TT(3)= 0.01 TF(3)= "PM" TV(3)= 1 (peak markers - on)
TT(4)= 0.1 TF(4)= "T4" TV(4)=0 (zero detector - off)
TT(5)= 90 TF(5)= "ER" TV(5)= 1 (end run)
TT(6)= 90 TF(6)= "T6" TV(6)=0 (stop program)
[TT = time in minutes, TF = function, TV = value: 1 means "on" and 0 means "off"]
A 25|il sample loop was used and samples containing 0.5 - l.Ofa.g/p.1 protein were 
injected at a time. Samples injected onto the column are monitored by UV absorbance at 
280nm. All samples are either spun at 1400rpm for 5 minutes or filtered using 
microcentrifuge filtration devices to remove particles and bacteria before injecting them 
into the column. First, 25|il of BioRad Gel Filtration Standards are injected and a 
standard curve of log of molecular weight versus retention time is plotted to determine 
the expected retention time of the RT. Also, buffer is injected by itself to identify 
background peaks. Fractions are collected and assayed for enzyme activity. Samples 
containing RT are pooled, concentrated, and stored at -70°C.
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TSK HPLC
For greater purification and analyses of protein based on molecular size, two TSK 
G3000 SW HPLC gel filtration columns were set up in series. Columns were equili­
brated with TSK buffer and run at room temperature. The high pressure limit was set at 
760psi, the maximum flow rate used was 0.3ml/minute, and AUFS was 0.5. As with the 
Superose 12 column, PT = 400,000, CS = 0.1, and AT = 1024. The integrator was 
programmed as follows: (for interpretation see previous page)
TT(1)=0.01 TF(1)= "T4" TV(1)= 1
TT(2)= 0.01 TF(2)= "T6" TV(2)= 1
TT(3)= 0.01 TF(3)= "PM" TV(3)= 1
TT(4)= 0.1 TF(4)= "T4" TV(4)=0
TT(5)= 120 TF(5)= "ER" TV(5)= 1
TT(6)= 120 TF(6)= "T6" TV(6)=0
RT samples of 0.1 to 0.5|ig/pl are loaded onto the column using a 25|il sample loop and 
were monitored by UV absorbance at 280nm. All samples are either spun at 1400rpm for 
5 minutes or filtered using the microcentrifuge filtration devices to remove particles and 
bacteria before injecting them into the column. 25(0.1 of BioRad Gel Filtration Standards 
were injected and a standard curve of log of molecular weight versus retention time was 
plotted to determine the expected retention time of the RT. Fractions are collected and 
assayed for enzyme activity. Samples containing RT are pooled, concentrated, and 
stored at -70°C.
Protein Concentration Determination
Protein concentration of fractions was determined by the Bradford Assay (72) 
using the Pierce Protein Assay k i t . First, a standard curve is set up using dilutions of an 
albumin standard (2mg/ml) in distilled water in a total volume of 1ml. Usually, 0, 5,10, 
15, 20, and 30|ig standard solutions were used. Add 1ml of Pierce Protein Reagent,
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mix, and read absorbance at 595nm. Make a sample blank using the same volume of RT 
buffer as will be used to measure the sample, plus water to 1ml. Add 1ml of Pierce 
Protein Reagent, mix, and read absorbance at 595nm. The standard curve is plotted 
using Cricket Graph III and a linear equation is obtained and used to calculate the 
concentration of the sample.
RT Polymerase Activity Assay
To identify samples containing RT, samples were screened for their ability to 
incorporate [3H]-dTTP using (rA)-(dT) 12-18 as a template. Reactions are started by 
adding 10(0.1 of enzyme solution to 40|ll reaction cocktail which contains final 
concentrations of 50mn Tris pH 8.5, 6mM MgCl2, 80mM KC1, 8mM DTT, .05% Triton- 
X 100, lOOpM dTTP, 2|0g (rA)-(dT) i2-is , and l |il (ljiCi) [3H]-dTTP. Samples are 
incubated at 37 °C for 30 minutes. Reactions are terminated by adding 800mls of ice cold 
stop solution and pipetted onto GF/C filters. Filters are washed with 6mls of stop 
solution followed by 1ml of 95% EtOH. Filters are placed in scintillation vials and 6mls 
of scintillation fluid added. For each assay, count one vial that has 10p.l of reaction 
cocktail plus 6mls of scintillation fluid. Vials are counted on a liquid scintillation counter 
and counts per minute (CPM) are converted to activity as follows:
CPM of the sample divided by CPM of 10)LXl of reaction cocktail 
equals activity (nmoles of [3H]-dTTP incorporated) per 10(xl of sample.
Units of RT activity are expressed as nmoles of [3H]-dTTP incorporated 
per ml.
Concentrating Protein Sample
The samples are concentrated using an Amicon Stirred Ultrafiltration Cell with an 
Amicon YM30 Diaflo ultrafilter membrane and nitrogen gas at 35 PSI. Fractions can be 
further concentrated using Amicon Centricon-30 microconcentrators spun in a Beckman 
model J2-21 centrifuge using a JA-20 rotor at 4.5rpm for 60 minutes or more.
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TCA Precipitation
In order to analyze dilute samples using SDS-PAGE, an aliquot of the sample is 
concentrated by precipitation with 10% TCA. Take 450p.l of the sample and add 50(il of 
100% TCA. Spin the sample at highest speed for 5 minutes at 4°C. Wash the sample 
twice with 1ml of 95% EtOH and Speed Vac to dryness. Add 10|al protein sample buffer 
and boil before loading onto polyacrylamide gel for electrophoresis.
SDS-PAGE
To analyze protein samples based on molecular weight, sodium dodecyl sulfate 
polyacrylamide gel electrophoresis (SDS-PAGE) was used according to the Laemmli 
method (73). 10% acrylamide mini-gels were run at 150 volts for 45 minutes to 1 hour. 
Gels were placed in Coomassie Brilliant Blue for 2 hours and destained for at least 2 
hours. Protein molecular weight markers from BioRad were used to make the standard 
curve for size estimations of sample bands.
Fluorescence Studies
Fluorescence studies were carried out at 25 °C using a quartz cuvette with a 1cm 
light path and a 2ml volume. For all fluorescence studies the following settings were 
used:
Amplifier AC (make sure chopper is on), Energy Mode, Auto Dynode Voltage: 
coarse = 1, Meter Selector Switch: dynode voltage, Manual Dynode Voltage: Int, adjust 
Manual Dynode Voltage knob until Dynode Voltage = 0.7 (700 volts), Zero Suppression 
Coarse knob: off, Response (SEC) Switch: 0.3, Coarse Sample Sensitivity: 0.1. Adjust 
Fine Sample Sensitivity for each sample.
Recorder X = 50 mv / cm (xl), Y = 50 mv / cm (xl)
Main Unit Excitation slit: lOnm, Emission slit: lOnm, Excitation wavelength: 
290nm, Emission wavelength: 342nm, Speed 60, Filter 31.
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All solutions to be read in the fluorimeter must be filtered and degassed. Open 
sample shutter and adjust sample sensitivity. Zero sample and set recorder pen on the 
lower left comer of the graph paper. The pen is moved manually for units along the x- 
axis. For dimerization studies the pen was moved along the x-axis three squares every 3 
minutes. The y-axis is moved automatically by the fluorimeter as it reads fluorescence. 
Points on the graph paper are marked manually by lowering and then raising the pen. 
Relative fluorescence is calculated by dividing the fluorescence intensity of a 100 % 
monomer solution by the fluorescence intensity of the sample. Data was corrected for 
background intensity of the buffer and Raman scatter using a buffer blank and filters.
Fluorescence Analysis of the Dissociation of RT Subunits
The effect of increasing acetonitrile concentrations on subunit interactions of wild 
type and mutant forms of RT was determined using intrinsic protein fluorescence 
measurements. 20fil of each sample (0.5jj.g/|xl = 7.5|iM) is mixed with varying amounts 
of 100% acetonitrile and fluorescence buffer to give final concentrations of 6(xM RT and 
either 0,2,4,8,12,16,18, or 20% acetonitrile. The samples were mixed and incubated 10 
minutes at room temperature to reach equilibrium. The entire sample is then added to 
1.975ml of fluorescence buffer and relative fluorescence intensity recorded. The 
procedure was carried out in triplicate for wild type RT and for each mutant and the data 
was averaged and plotted as relative fluorescence on Cricket Graph III.
Fluorescence Analysis of the Association of RT Subunits
To analyze dimerization, the re-association of subunits which have been 
dissociated with 17% acetonitrile was observed over time. First, 19.5(xl of RT (2|ig/|il) 
was mixed with 4|il of 100% acetonitrile and incubated 10 minutes at room temperature 
to dissociate the subunits. Then the mixture was added to 1.976ml of fluorescence buffer 
in a quartz cuvette which dilutes the acetonitrile concentration 10-fold and allows the
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subunits to re-associate. The intrinsic fluorescence was recorded every 3 minutes for 60 
minutes. The procedure was carried out in triplicate for wild type RT and for each 
mutant and the data averaged. The data was converted to relative fluorescence and 
plotted using Cricket Graph HI.
Polymerase Activity Analysis of the Dissociation of Subunits
The effect of increasing acetonitrile concentrations on subunit interactions of wild 
type and mutant forms of RT was determined using the RT polymerase activity assay. 
Each RT sample (0.5|J.g/|ri) was diluted 1/10 in enzyme diluent and 1(0.1 removed and 
added to each of 11 tubes containing varying amounts of 100% acetonitrile and enzyme 
diluent to give final concentrations of either 0, 2, 4, 6, 8, 10, 12, 14, 16, 18, or 20% 
acetonitrile in a final volume of lOjLtl. The samples were incubated 10 minutes at room 
temperature to reach equilibrium. The entire contents of the tube was added to 40(41 of 
RT polymerase activity reaction cocktail to initiate the reaction and the assay was carried 
out as described for the RT polymerase activity assay described previously. Each 
experiment was repeated three times and the data averaged and the results plotted using 
Cricket Graph III.
Analytical Gel Filtration Analysis of Dissociation
Two TSK G3000 SW HPLC gel filtration columns were set up in series at room 
temperature and equilibrated in a buffer containing 8% acetonitrile by programming the 
HPLC pump as follows: 84% of reservoir #1 which contains 50mM Tris-Cl pH 7.5 and 
lOOmM KC1, and 16% of reservoir #3 which contains 50% acetonitrile. The high 
pressure limit was set at 800psi, the flow rate was 0.3ml/min, and the AUFS was set at 
0.02. The integrator was programmed the same as it was for protein purification. The 
sample was prepared by combining 40|J.l of RT (2(0g/(0l), 8(0l of 50% acetonitrile, and 
2(tl of buffer (50mM Tris-Cl pH 7.5 and lOOmM KC1). The sample was incubated for 10
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minutes at room temperature before being injected into the HPLC column. 50|il of 
sample was injected into a 25[il sample loop.
RNase H Activity
Assays for RNaseH activity were performed essentially as described by Moen and
coworkers (74). First, make up 750|xl of reaction cocktail: 660|il of sterile Milli-Q H2O,
75JJ.1 of lOx annealing buffer, 7.5|xl poly(dT) 33.4pmols/|jl, and 7.5|il [3H]poly(rA)
32.5pmols/|il. Mix and put 150|il into each of five 0.5ml tubes, which will be for five
enzyme RNase H assays. Run annealing program on the thermocycler:
Step 1 90° C 0 minutes 
Step 2 90° C 3 minutes 
Step 3 60° C 0 minutes 
Step 4 60° C 0 minutes 
Step 5 25° C 60 minutes 
Step 6 25° C 0 minutes
Label five stop tubes for each reaction tube as 0, 15, 30, 45, and 60 minutes, add 800p.l
of 10% TCA solution to each tube, and place on ice. Start each assay 30 seconds apart.
At time 0 for each assay add enzyme, mix, remove a 25(0.1 aliquot and put it in the
appropriate stop tube, and place the rest of the reaction mix in a 37 °C water bath. At the
appropriate times remove 25|il aliquots and add to the stop solution on ice. 5|il of
BSA(15mg/ml) was added to each tube after the reactions were stopped. The samples
were filtered on nitrocellulose and washed with approximately lOmls of 10% TCA
solution. The filters were rinsed with l-2mls of ethanol and counted in 5mls of
scintillation cocktail and counted on a Beckman Liquid Scintillation Counter. The assay
was repeated three times for each enzyme and the counts averaged. An assay was run in
which no enzyme was added as a negative control. For a positive control, 16U of AMV-
RT was added to 150(0.1 RNase H reaction cocktail. For wild type RT and for each
mutant RT, l |il of a l(ig/|il enzyme solution was added to 150(ll of RNase H reaction
cocktail.
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RESULTS
Growth Curve for New Yeast Strain, XS95-6C
In order to use this strain of Saccharomyces cerevisiae for cloning and expression 
of the mutant forms of RT5, it was helpful to determine at what times different stages of 
cell growth occur. The growth curve can be divided into three main phases: lag phase, log 
phase, and stationary phase. Most cloning and gene expression activities are carried out 
during the log phase. The log phase is further divided into early-log which is characterized 
by a cell density of < 107 cells/ml, mid-log phase has a cell density of 1 to 5 x 107 cells/ml, 
and late-log which has a cell density from 5 x 107 to 2 x 108 cells/ml. The following 
growth curve was obtained by taking ODgoo measurements of the cell culture as described 
in Methods over a 44 hour period (see Figure 10). As can be seen in this graph, early log 
phase occurs at 14 to 20 hours, mid-log at 20 to 25 hours, and late-log at 25 to 33 hours. 
Transformation of yeast cells is most effective when yeast cells are at the beginning of mid­
log phase or 0.5 ODgoo. Yeast cells for plasmid preparations are usually grown to the 
stationary phase for maximum production of plasmids. The optimal growth phase for 
expression and synthesis of mutant RT enzyme was determined in another experiment 
described later.
Isolation of pAB24/RT5 from Yeast and Transformation into E. coli
The first step in creating a site-specific mutant of HIV-1 RT using PCR 
mutagenesis was to obtain template DNA which was pAB24/RT5, the plasmid containing 
the gene for the wild type enzyme. pAB24/RT5 is a shuttle vector which was transferred to
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Figure 10. Growth curve for yeast strain XS95. The graph shows different phases of 
growth over a 44 hour period in YPD medium. Cell density is quantitated by measuring 
light absorbance at 600nm using a 1cm plastic cuvette in a Bausch and Lomb spectro­
photometer and is expressed as optical density (OD).
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Escherichia coli (E. coli. )  for recombinant DNA work because plasmid amplification and 
preparation is more efficient using E. co li. We used the strain HB101, which is easily 
transformed and provides large scale growth and production of plasmid. The plasmid was 
isolated from yeast, and transformed into competent HB101 E. coli cells as described in 
the Methods section. One colony grew on the selective plate which was used to grow an 
overnight culture. A plasmid miniprep was carried out on 1.5mls of this overnight culture 
and the rest was stored in 15% glycerol at -70°C. The isolated plasmid was digested with 
BamH-1 and Sal-1 restriction enzymes in one reaction, and Hind-3 in another reaction. 
The presence of pAB24/RT5 was confirmed by the enzyme digest patterns of bands 
visualized in a 1% agarose gel (see Figure 11). BamH-1 and Sal-1 cut the plasmid into 2 
fragments, Hind-3 cut pAB24/RT5 into 6 fragments. The size of the bands on the gel were 
estimated using a standard curve based on the migration distances of fragments of Lambda 
DNA BstE-2 digest.
More of the transformed HBlOlis. coli cells were grown from -70°C glycerol 
stock cultures and several minipreps carried out in order to obtain enough plasmid DNA to 
serve as template for PCR mutagenesis. A total of 50|il of a 12|ig/(il solution of purified 
plasmid DNA was obtained, which was more than enough for PCR procedures since only 
0.1 to 250ng of template DNA were needed for each reaction. Large amounts of plasmid 
DNA, pAB24/RT5, were needed later for putting the mutated fragment of DNA back into 
the cloning vector.
PCR Mutagenesis of RT5
A procedure for creating a single base pair substitution at amino acid position L289 
of HIV-1 RT using PCR mutagenesis was designed and is summarized in Figure 5 of the 
Methods section. In order to determine if the first set of PCR reactions for making 
fragment A and fragment B worked, 5[il aliquots from each of the 100|il PCR reaction 
mixes were analyzed on a 1% agarose gel. Figure 12 shows PCR fragments A and B.
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Figure 11. 1% agarose gel electrophoresis showing wild type plasmid isolated from 
transformed HB101 E. coli and digested with restriction enzymes. Numbers represent the 
size of fragments in kilobases. a) standard size marker: Lambda DNA Bste digest, b) and 
c) pAB24/RT5 digested with BamH-1 and Sal-1, d) pAB24/RT5 digested with Hind-3.
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.




2.3 H H H 2.7





Reproduced with permission of the copyright owner. Further reproduction prohibited without permission
Figure 12. Preparative 1% agarose gel showing PCR fragments, a) PCR fragment A, 
b) PCR fragment B. The fragments are produced in separate PCR experiments and must 
be isolated from the gel, purified and combined in a third PCR experiment to produce the 
PCR mutated fragment C. Numbers represent fragment sizes in kilobases.
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Fragment A is synthesized using primers 1 and 2 (for making mutant L289R) and primers 
1 and 4 (for making mutant L289P). Fragment B is synthesized using primers 3 and 6 (for 
making mutant L289R) and primers 5 and 6 (for making mutant L289P). All of the A and 
B PCR products were isolated from the PCR reaction mixture by running on a preparative 
agarose gel using low melting temperature agarose. The preparative gel was run using 
large sample wells as shown in Figure 12. Once the A and B fragments were isolated and 
purified they were combined in a second PCR reaction using only the outside primers 1 and 
6, which resulted in the formation of fragment C. A comparison of the different sizes of all 
3 fragments can be seen in Figure 13. Fragment C, which contains the desired base pair 
substitution, was isolated from the PCR reaction mix by running on a preparative gel as 
described for fragments A and B. Once a large quantity of purified PCR mutated fragment 
C was obtained, it was digested with AlwN-1 and Sal-1 to produce the necessary cohesive 
ends for placing the mutated fragment back into the expression vector (Figure 14).
Placing Mutant Fragment C into Expression Vector
The procedure for placing mutated fragment C into pAB24 is summarized in Figure 
9 of the Methods section. The first step of digesting pAB24/RT5 with BamH-1 and Sal-1 
and purifying the DNA fragments was repeated many times to obtain large amounts of 
BamH-l/Sal-1 large and small fragments (Figure 15). All BamH-l/Sal-1 large fragment 
samples were isolated, purified, pooled, quantified, and stored at -20°C. The BamH- 
l/Sal-1 small fragment samples were also isolated, purified, and quantified, but then they 
were digested with AlwN-1 and Pvu-2. The double digest was run on a 1% agarose gel 
and the 1,025 base pair BamH-l/AlwN-1 fragment was isolated and purified. The ligation 
step was done in two steps, and the best conditions and concentrations of fragments was 
determined empirically. The BamH-l/AlwN-1 fragment was first ligated to the mutant 
AlwN-l/Sal-1 fragment to produce a BamH-l/Sal-1 fragment which contained the 
mutation. Then the BamH-l/Sal-1 large fragment containing the body of the plasmid was
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Figure 13. 1% agarose gel showing all three PCR fragments: a) PCR fragment A, 
b) PCR fragment B, and c) PCR fragment C which is made by combining fragments A 
and B. Numbers indicate the size of each fragment in kilobases.
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Figure 14. Preparative 1% agarose gel for isolating PCR mutated fragment C which has 
been digested with AlwN-1 and Sal-1 restriction enzymes. Numbers indicate fragment size 
in kilobases. The fragments visible in lanes a) and b) were cut out and purified by phenol 
extraction and ethanol precipitation.
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Figure 15. Preparative 1% agarose gel showing multiple BamH-l/Sal-1 double digests 
of pAB24 in lanes a-d. Numbers are the fragment sizes in kilobases. Both large and small 
fragments are isolated from the gel, purified, and used for inserting mutated fragment C 
into pAB24 expression vector.
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added to this same ligation mixture and incubated again to produce closed, circular plasmid 
DNA containing the mutated RT gene. For each ligation step the fragments being ligated 
possessed overhangs with different restriction sequences at each end so they could combine 
in only one possible direction. The ligation mixture was directly used to transform HB101 
E. coli cells which were spread onto LB + Ampicillin plates (Figure 16). The ligation/ 
transformation experiment for each mutant produced only 1 to 4 colonies per plate and 3ml 
overnight cultures were grown from each colony in LB + Ampicillin broth. 1.5mls of the 
overnight culture was used to make glycerol stock cultures and the rest of the overnight 
culture was used to do a mini-plasmid prep for restriction enzyme analysis using BamH-1 
and Sal-1 to verify that pAB24/RT was present. The successfully cloned, mutated RT gene 
was then ready to be sequenced to verify that the desired site-specific mutation had been 
produced.
DNA Sequencing
The region of the RT gene that was sequenced was the region that was manipulated 
by PCR mutagenesis to produce the site-specific mutant. This sequence corresponds to the 
PCR fragment C which is bound by AlwN-1 and Sal-1 restriction sites. The same primers 
that were used for PCR mutagenesis were used for DNA sequencing using Promega's 
Silver Sequence method. Each mutant was sequenced over the entire 1,040 bases which 
were PCR amplified, and for each sequencing experiment an average of 200 bases could be 
read. Sequences that were questionable were repeated and no other mutations were found. 
Sequences showing the desired mutations are shown in Figures 17 and 18. As can be seen 
in Figure 17 the T has been changed to a G to produce a codon for arginine instead of 
leucine for the L289R mutant. Figure 18 shows that the T has been changed to a C to 
produce the codon for proline for the L289P mutant.
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Figure 16. Photograph of an LB + ampicillin selective plate with three colonies of 
HBlOlis. coli transformed with the plasmid, pAB24/RT5Ml, containing the mutated 
RT gene. Only the bacteria which contain this plasmid will grow on the selective 
plate. Further confirmation that the correct plasmid is in the HB101 E. coli cells is 
obtained by growing an overnight culture from one of the colonies, doing a plasmid 
prep, and digesting die plasmid with BamH-1 and Sal-1.
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Figure 17. Photograph of a DNA sequencing gel showing the T to G mutation which 
will result in the amino acid change, L289R. The sequence shown on the left hand side of 
the picture is read from the bottom, which is the 5' end, to the top, which is the 3' end of 
the sequence.
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Figure 18. Photograph of a DNA sequencing gel showing the T to C mutation which 
will result in the amino acid change, L289P. Part of the sequence containing the mutation 
is shown on the left and is read from the bottom (5'end) to die top (3'end).
F “
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Yeast Transformation
The yeast strain XS95 was successfully transformed with both mutant plasmids 
using the spheroplast method (70). Several different quantities of DNA were used, and all 
were successful. A critical factor was the optical density of the yeast cell culture that was to 
be transformed, which should be no more than 0.5 ODgoo. Also, sterile conditions must be 
maintained throughout the procedure and spheroplasts must be treated very gently. Yeast 
colonies that grew embedded in the selective regeneration agar formed star shaped colonies 
while those that grew on top of the agar formed the normal smooth, round colonies (see 
Figure 19). Several colonies were picked and overnight cultures grown in Leu minus rich 
medium. Half of the overnight culture was stored as a glycerol stock and the other half 
analyzed by restriction enzyme digest with BamH-1 and Sal-1 (see Figure 20). Several 1 
liter cultures of XS95 yeast containing the mutated pAB24/RT were grown for large scale 
protein preparations.
Yeast Expression Experiment
This experiment was carried out to determine if and when the yeast strain XS95 
carrying mutated plasmid would express the RT gene. For yeast expression of the RT gene 
to be initiated, the GAPDH promoter must be turned on by a glucose deficiency. 
Decreased levels of glucose in the YPD medium occurs as the yeast cells grow and divide 
and metabolize glucose. As glucose levels decrease, the GAPDH promoter is activated and 
expression of RT is amplified. The data summarized in Table 1 shows that over time, as 
the OD600 of the culture increased, the glucose levels decreased and RT activity in protein 
extracts increased. The optical density of the cell culture began to slow down after 14 
hours which is the same time that glucose levels dropped to undetectable levels (see Figure 
21), however, RT activity continued to increase (Figure 22). As can be seen in Figure 23, 
protein concentration measurements parallel RT activity and reflect the synthesis of large 
amounts of protein. After 18 hours of growth, RT activity decreased slightly indicating
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Figure 19. Photograph of a leucine minus selective plate showing colonies of yeast 
strain XS95 transformed with the mutated plasmid, pAB24/RT5Ml. Several of the 
colonies were picked for growing up overnight cultures for plasmid preps which were 
analyzed by restriction enzyme digests to confirm that the correct plasmid was present in 
the yeast.
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Figure 20. Photograph of a 1% agarose gel showing plasmid from transformed yeast 
digested with BamH-1 and Sal-1 in lanes d and e. Lanes a and b show undigested plasmid 
and lane c shows the Lambda DNA marker.
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Table 1. Mutant RT expression experiment in yeast strain XS95. Yeast cells transformed 
with the mutated plasmid are grown for 24 hours in YPD medium. Samples of the culture 
are taken every hour to measure cell density, glucose level, pH, protein concentration, and 
RT activity.
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0 .061 .064 0 240 7
1 .084 3.251 240 7
2 .07 3.869 .012 240 7
3 .105 2.856 240 7
4 .107 2.959 .042 240 7
5 .156 2.633 240 7
6 .251 5.075 .110 240 7
7 .395 4.754 240 7
8 .542 13.625 .243 240 7
9 .769 15.775 240 7
10 .998 14.391 .297 120-240 7
11 2.380 17.358 120-240 7
12 4.250 20.744 .463 120-240 7
13 5.330 18.851 120 7
14 5.730 46.059 .542 60 7
15 5.760 79.524 0 7
16 5.870 93.025 .594 0 7
17 5.900 103.376 0 7
18 6.410 154.172 .660 0 7
19 6.130 133.339 0 7
20 6.040 125.456 .506 0 7
21 6.640 144.906 0 7
22 6.750 159.916 .494 0 7
23 7.020 165.848 0 7
24 7.290 200.543 .639 0 7
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Figure 21. Mutant RT expression experiment in yeast strain XS95. The cell culture is 
grown in YPD medium for 24 hours and samples analyzed every hour. The graph has a 
double Y-axis showing glucose concentration and cell density over culture incubation 
time. —— Glucose (mg/dl) 3K Cell Density (ODg00)
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Figure 22. Mutant RT expression experiment in yeast strain XS95. The cell culture is 
grown in YPD medium for 24 hours and samples analyzed every hour. The graph has a 
double Y-axis showing glucose concentration and RT Activity over culture incubation 
time. — Q —  Glucose (mg/dl) »■ ....... Activity (nmol/ml)
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Figure 23. Mutant RT expression experiment in yeast strain XS95. The cell culture is 
grown in YPD medium for 24 hours and samples analyzed every hour. The graph has a 
double Y-axis showing protein concentration and RT Activity over culture incubation 
time. “ “ O - -  Protein Concentration (p.g/p.1) ^  Activity (nmol/ml)
It
























either a drop in expression of RT or destruction of the protein by yeast proteases. Since 
this yeast strain is not protease negative, it may synthesize proteases in response to the 
production of a non-native protein, which could make RT isolation difficult or impossible. 
However, after 3 more hours the RT activity began to rise again, which may mean that RT 
synthesis became greater than protease degradation, or that RT was being converted to 
heterodimer, the mature form of the enzyme. For large scale protein preps the XS95 yeast 
should be grown 25 hours before being harvested for protein purification. Protease 
inhibitors must be included throughout the purification procedure and all solutions 
containing RT must be kept ice cold to further inhibit protease activity.
Comparative Purification of Mutants on P l l  Column:
Whatman PI 1 cellulose phosphate contains an ester-linked phosphate functional 
group which acts as a cation exchanger. The cellulose phosphate will bind or release 
molecules depending on the charge of the molecule and the ionic strength of the eluant 
buffer. P l l  also acts as a specific adsorbent for enzymes such as DNA polymerases that 
have a high affinity for phosphate ions. The phosphate groups on the PI 1 column may 
resemble the phosphate group on dNTPs, binding to the dNTP substrate binding site on the 
enzyme. When cell lysate containing RT is passed through the PI 1 column using standard 
RT buffer (RTB), which contains 50mM KC1, RT will bind to the phosphorylated 
cellulose. The column is washed with 50mM KC1 RTB to remove any molecules not 
bound to the cellulose phosphate. When a buffer salt gradient is passed through the 
column RT will be released from the cellulose phosphate at a specific salt concentration. In 
a 50-800mM KC1 gradient in RTB, wild type RT elutes in 300-400mM KC1.
The purification procedure was repeated three times for each mutant under the same 
conditions in order to observe any differences in elution characteristics which may indicate 
changes in molecular charge of the enzyme. Each experiment started with growth and 
expression of 1 liter of XS95 cells containing the mutated RT gene. Protein was
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precipitated from the cell culture using ammonium sulfate, dialyzed to remove salt, and 
loaded in a volume of 200mls onto the PI 1 column. While running a 50-800mM KC1 
gradient in RTB with a pump flow rate of 0.5ml/minutes, samples were collected in a 
fraction collector set at 16 minutes /tube. Fractions were assayed for RT polymerase 
activity and protein concentration and plotted versus elution volume using Cricket Graph 
III (Figures 24-31). From this graph it could be determined at what volume the enzyme 
elutes. Then, by plotting the elution volume versus the salt concentration, the salt 
concentration in which each mutant elutes could be determined. The results for the three 
P l l  preps of mutant L289R are shown in Figures 24-26. Figure 27 shows that L289R 
elutes in an average of 118mM to 245mM KC1 in RTB. The results of the three L289P 
P l l  preps are shown in Figures 28-30. Figure 31 shows that mutant L289P elutes in an 
average of 121mM to 247mM KC1 in RTB. Both mutant enzymes eluted at lower KC1 
concentrations than wild type RT which elutes in 300-400mM KC1, however, the elution 
characteristics of the two mutants were similar to each other. These results indicate that the 
mutations may have affected the structure of the enzymes and dimer stability so that the 
mutants elute from the P l l  column in a lower ionic strength solution than wild type 
enzyme.
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Figure 24. Comparative purification of mutants on the PI 1 column: Mutant L289R 
prep#l. The graph shows activity as nmol/ml (— 0 — ) and protein concentration 
as absorbance at 595nm (- - O "  -). Peak RT activity occurs at 145mM KC1. The 
mutant RT elutes in a range of 130 to 230mM KC1.
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Figure 25. Comparative purification of mutants on the PI 1 column: Mutant L289R 
prep #2. The graph shows activity as nmol/ml ( — 0 — ) and protein concentration 
as absorbance at 595nm (- ■ o »  ■). Peak RT activity occurs at 163mM KC1. The 
mutant RT elutes in a range of 135 to 258mM KC1.
ilk'

























Figure 26. Comparative purification of mutants on the PI 1 column: Mutant L289R
prep #3. The graph shows activity as nmol/ml (  $  1) and protein concentration
as absorbance at 595nm (■ - O-- -). Peak RT activity occurs at 97mM KC1. Mutant 
RT elutes in a range of 88 to 248mM KC1.
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Figure 27. Comparative purification of mutants on the P l l  column: Mutant L289R, 
average of three preps. The graph shows the linear salt gradient versus elution volume. 
Mutant L289R elutes in an average of 118-245mM KC1.
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Figure 28. Comparative purification of mutants on the PI 1 column: Mutant L289P 
prep#l. The graph shows activity as nmol/ml ( #  1) and protein concentration
as absorbance at 595nm (- - O-- ■). Peak RT activity occurs at 180mM KC1. The 
mutant RT elutes in a range of 150-225mM KC1.

























Figure 29. Comparative purification of mutants on the PI 1 column: Mutant L289P 
prep #2. The graph shows activity as nmol/ml ( Q  ) and protein concentration 
as absorbance at 595nm (■ ■ O "  -). Peak RT activity occurs at 88mM KC1. Mutant 
L289P RT elutes in a range of 78-239mM KC1.
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Figure 30. Comparative purification of mutants on the PI 1 column: Mutant L289P 
prep #3. The graph shows activity as nmol/ml ( n.- f l —■) and protein concentration 
as absorbance at 595nm (- - o - -  -). Peak RT activity occurs at 154mM KC1. Mutant 
L289P RT elutes in a range of 135-276mM KC1.
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Figure 31. Comparative purification of mutants on the P l l  column: Mutant L289P, 
average of three preps. The graph shows the linear salt gradient versus elution volume. 
Mutant L289P elutes in an average of 121-247mM KC1.
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Completion of Mutant Purification
After the initial PI 1 purification step was completed and the fractions containing the 
RT peak pooled, a 40ml average sample volume was obtained. The samples from two out 
of the three preps for each mutant were concentrated down to 2mls and stored at -20°C in 
the non-defrosting freezer. The other 40 ml samples, 12.5mg for the L289R mutant and 
35mg for the L289P mutant, from each P l l  prep were loaded onto the Affi-Gel Blue 
column (see Figures 32 and 33). After pooling, desalting and concentrating fractions from 
each mutant prep, 3.1mg in 1.5ml was obtained for the L289R mutant and 5.3mg in 2ml 
was obtained for the L289P mutant . These samples were then passed through the 
Superose 12 gel filtration column in 25pl injections and the fractions collected, pooled, and 
concentrated (see Figures 34 and 35). For the L289R mutant, 500|il of a 1.8|ig/|il sample 
was obtained. For the L289P mutant, 500pl of a 2|j.g/|Lil sample was obtained. The 
retention times of peaks observed coming off the Superose 12 column when L289R was 
injected showed a standard deviation of 4.31 minutes with an average of 85.97 minutes. 
Using the standard curve shown in Figure 36 to calculate the estimated molecular weight of 
this peak, the sample is approximately 98,000 Da. This value is close to 99,000 which 
would be the average molecular weight of a mixture of monomers (66,000 Da) and dimers 
(132,000 Da), which is what we expect to observe since the Superose 12 column cannot 
resolve monomers from dimers. The range of retention times observed for the L289R 
mutant, 81.66 to 90.28, overlaps the range observed for the L289P mutant which was 
82.31 to 90.15 minutes. The average retention time for the L289P mutant was 86.23 
minutes which equals approximately 96,000Da based on the standard curve. This estimated 
molecular weight value is slightly less than the value observed for L289R which may mean 
that there is a greater percentage of monomers present in the L289P sample.
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Figure 32. SDS-PAGE of the mutant L289R prep showing pools from Affi-Gel Blue 
column. Fractions were collected from the Affi-Gel Blue column and assayed for RT 
activity and protein concentration. Fractions containing peak RT activity were pooled, 
concentrated, and desalted. Lane d shows pool #2 which has the greatest RT 
activity; lanes a and g are molecular weight markers; lane b is crude extract; lane c is pool 
#1; lane e is pool #3; and lane f is pool #4. Numbers represent apparent molecular weight 
in kilodaltons.
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Figure 33. SDS-PAGE of mutant L289P prep showing fractions collected from the Affi- 
Gel Blue column. 500(J.l of each fraction was TCA precipitated, resuspended in 15(il of 
sample buffer, and run on a 10% polyacrylamide gel. Lane a shows molecular weight 
markers; lanes b-h are fractions 6, 8, 10, 19, 22, 24, and 25. Numbers represent the 
apparent molecular weight in kilodaltons. The greatest amount of mutant RT is in fraction 
#10, lane d.
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Figure 34. SDS-PAGE analysis of mutant L289R purified by the Superose 12 column. 
Fractions collected from the column were analyzed for RT activity and samples containing 
peak activity were pooled and concentrated. 10(J.l of this pool was run on the 10% poly­
acrylamide gel in lane b. Lane c shows wild type RT and lane a shows the molecular 
weight markers. The numbers are the apparent molecular weights in kilodaltons.
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Figure 35. SDS-PAGE analysis of mutant L289P purified by the Superose 12 column. 
Fractions collected from the column were analyzed for RT activity and samples containing 
peak activity were pooled and concentrated. 100|il of this pool was TCA precipitated, 
resuspended in sample buffer, and run on the 10% polyacrylamide gel in lane b. Lane c 
shows wild type RT and lane a shows the molecular weight markers. The numbers are 
the apparent molecular weights in kilodaltons.
•
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Figure 36. Graph of the protein standard curve for the Superose 12 FPLC gel filtration 
column. 25|0.1 of BioRad gel filtration standards were injected onto the column and the 
retention time for each protein peak was plotted against the log of the molecular weight of 
the protein peak. Point A = 158KDa, point B = 44KDa, point C = 17KDa, and point D =
1.35KDa. The equation for the standard curve was calculated by Cricket Graph III to be: 
y = -0.039x + 8.344, and was used to determine the expected retention time for mutant 
RT based on the molecular weight of the monomer and dimer forms of RT.
    .   ......................
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The two mutant RT samples collected from the Superose 12 column were injected 
onto tandem TSK gel filtration columns for final purification . The RT peak fractions 
collected from this column were pooled and concentrated as before. The final yield of 
purified protein was 250|il of the L289R mutant at 1.08|ig/|il, and 500|il of the L289P 
mutant at 1.02|4.g/p.l. The samples were run on a 10% SDS-PAGE gel (see Figure 37) 
which was scanned by a densitometer to determine the percent purity of each mutant RT 
sample.
Densitometric Gel Scan
Densitometric scans of the gel in Figure 37 were made on a GelScan XL (2.1) 
densitometer with the permission of Dr. Castora at Eastern Virginia Medical School. 
Quantitation of the peaks was made by cutting out the peaks and weighing them. The scan 
of the standard markers in lane #4 of the gel is shown in Figure 38. Wild type RT5 makes 
up 81% of the total protein in sample lane #1 as measured by the scan shown in Figure 39. 
The L289R mutant RT in lane #2 makes up 84% of the protein in this sample as measured 
by the scan shown in Figure 40. Mutant L289P RT makes up 66% of the total protein in 
this sample as determined from the scan shown in Figure 41. These values must be taken 
into consideration when making calculations involving protein concentration. For example, 
specific activity is based on units of RT activity divided by the quantity RT in the sample. 
The amount of RT is equal to the protein concentration determined by the Pierce protein 
assay multiplied by the percent of RT measured by the densitometer.
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Figure 37. SDS-PAGE analysis of different forms of RT after final purification step. 
Lane a is wild type RT, lane b is mutant L289R, and lane c is mutant L289P. Molecular 
weight markers are shown in lane d. Numbers represent the apparent molecular weight in 
kilodaltons.
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Figure 38. Densitometric gel scan of molecular weight markers in lane #4 of the 
SDS-PAGE gel shown in figure 37.
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
14.4 kDa
94
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
Figure 39. Densitometric scan of wild type RT5 in lane #1 of the SDS-PAGE 
gel shown in Figure 37. Peak sizes were quantitated by cutting them out and 
weighing them. The RT5 peak was determined to make up 81% of the total 
protein in the sample.
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Figure 40. Densitometric scan of mutant L289R in lane #2 of the SDS-PAGE 
gel shown in figure 37. This mutant was determined to make up 84% of the total 
protein in the sample.
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Figure 41. Densitometric scan of mutant L289P in lane #3 of the SDS-PAGE gel 
shown in figure 37. This mutant was found to make up 66% of the total protein in 
the sample.
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Effect of RT Concentration on RT Polymerase Activity
In theory, as enzyme concentration is increased, the activity of the enzyme is ex­
pected to increase in a linear relationship. However, in practice, the relationship is linear 
only at a certain enzyme concentrations. In order to determine the best enzyme concen­
tration for activity assays several different dilutions were prepared using l|lg/jjl samples of 
each mutant RT . As can be seen in Figure 42, dilutions in the range of 1/120 to 1/240, 
which have final concentrations of 4.2ng/|il to 8.3ng/|il, were in the linear region of the 
curve for both mutant forms of RT. Mutant RT concentrations in this range will be used 
for all experiments involving RT polymerase activity.
Specific Activity of RT Mutants
The specific activity of RT is defined as the nmoles of [3H]dTTP incorporated per 
fig of RT. For determining the specific activity of each mutant RT, the RT polymerase 
activity assay was carried out using a dilution of enzyme in the linear range of RT activity 
as determined above. The assay was carried out in triplicate for each enzyme sample and 
the nmoles of substrate incorporated per |ig of enzyme determined. The specific activity 
measurements must be corrected by multiplying them by the percent of RT in each enzyme 
sample as determined by the densitometric scans described above. The results are 
summarized in Figure 43 and show that mutant L289P has significantly lower specific 
activity than wild type RT, but is not significantly different from mutant L289R. Mutant 
L289R also appears to have lower activity than wild type RT but when error is taken into 
consideration it is not significantly different. The lower specific activity of the L289P 
mutant may be caused by impurities in the sample since it was determined to be only 66% 
of the total protein in the sample. These results raise some interesting questions about how 
these two mutants compare with each other as well as how they compare with wild type 
enzyme. These questions will be answered by further comparisons of enzyme behavior.
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Figure 42. Experiment to determine the enzyme concentrations which have a linear 
relationship with enzyme activity. Panel A is a graph of the activity of mutant L289R 
at different concentrations. Dilutions in the range of 1/120 to 1/240 were in the most 
linear region of the curve. This means that RT concentrations from 4.2ng/(il or 
63.6nM to 8.3ng/|il or 125.8nM should be used for activity assays. Panel B is a graph 
of the activity of mutant L289P at different concentrations and the results were the 
same as for L289R.
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Figure 43. Specific activity determinations for RT mutants L289R and L289P. 
The specific activity of the mutants is compared to wild type RT which has been 
previously determined (11).
I*-:
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0
RT5 L289R L289P
RT Sample Specific Activity
Wild Type RT5 14.80 ±  2.7 (11)
Mutant L289R 11.33 ± 2 .1 9
Mutant L289P 8 .39+  1.12
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Fluorescence and the Dissociation of Subunits in Increasing Concentrations 
of Acetonitrile
Earlier studies have already shown that fluorescence can be used to analyze 
dimerization of HIV-RT (32). The heterodimeric enzyme contains a total of 37 tryptophan 
residues, 19 on the p66 subunit and 18 on the p51 subunit. As the molecule undergoes 
conformational changes, some of the tryptophans either become buried or exposed 
resulting in a change in fluorescence intensity of the molecule and the solution as a whole. 
Divita and coworkers found that when looking at the dissociation and reassociation of RT 
subunits there was a significant (25%) change in the fluorescence intensity which allowed 
the use of this method to do kinetic studies of dissociation and dimerization (32). 
Previously, only analytical gel filtration (29, 40), analytical ultracentrifugation (33, 40), 
and circular dichroism spectroscopy (34, 40) have been used to study association and 
dissociation of RT subunits. The fluorescence method has been shown to be as reliable as 
these other methods and even better for studying dissociation because it can measure 
changes that occur within a few seconds (32). The fluorescence method of analyzing 
subunit interactions has also been shown to directly correlate with RT polymerase activity. 
Acetonitrile is an organic solvent which, at a concentration of 17% to 20%, has been 
shown to dissociate the dimer into monomers without causing complete unfolding of the 
subunits (29, 32, 75).
The dissociation of subunits in increasing concentrations of acetonitrile was 
compared for wild type RT and the two RT mutants, L289R and L289P. The results, 
shown in Figure 44, are three sigmoidal curves similar to the curve obtained by Divita's 
group (32). The two RT mutants created in our lab showed a significantly different 
dissociation pattern from wild type RT in the region between 6 and 16% acetonitrile. Both 
mutants appear to dissociate into monomers at lower concentrations of acetonitrile than 
wild type RT. The wild type RT was 50% dissociated into monomers at approximately
11.5% acetonitrile whereas both of the mutants were 50% dissociated at 7.5%. All three
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Figure 44. Fluorescence studies showing the dissociation of subunits in increasing 
concentrations of acetonitrile. Relative fluorescence is expressed as a fraction of the 
observed intrinsic fluorescence of the sample divided by the fluorescence of 100% 
monomeric RT. As the percentage of acetonitrile in the sample increases, more of the 
subunits dissociate resulting in increased fluorescence. The results for all three forms 
of RT are shown in the graph.
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samples of RT were completely dissociated into monomers at 18% acetonitrile. The two 
mutants differed slightly from each other at concentrations above 8% acetonitrile. Mutant 
L289R maintained a slightly higher percentage of dimers at higher concentrations of 
acetonitrile than mutant L289P which was completely dissociated at 16% acetonitrile.
RT Polymerase Activity and the Dissociation of Subunits in Increasing 
Concentrations of Acetonitrile
A previous study has shown that RT subunit dissociation can be directly correlated 
with RT intrinsic fluorescence as well as with RT polymerase activity (32). The RT 
polymerase activity assay has an advantage over fluorescence in that it requires a much 
smaller quantity of enzyme. However, fluorescence is important because, although RT 
activity is affected by subunit interactions, fluorescence is a direct measurement of subunit 
interactions. Therefore, it was desirable to correlate the fluorescence observations that the 
mutants appeared to dissociate more easily than wild type RT, and also that L289P may 
dissociate slightly more readily than mutant L289R with effects on RT activity. The RT 
polymerase activity assay was used for another comparative study of the dissociation of RT 
subunits in different concentrations of acetonitrile. The samples were set up in different 
concentrations of acetonitrile just as they were for the fluorescence study, plus three 
additional concentrations were used. The preparation of the sample mixture was timed so 
that the enzyme would be incubated with the acetonitrile for 10 minutes before starting the 
activity assay to allow the effect of acetonitrile on subunit interactions to reach equilibrium. 
Figure 45 shows that as the enzyme was incubated in higher percentages of acetonitrile, the 
activity of the enzyme decreased due to dissociation of the subunits. This graph shows that 
both mutants are significantly different from wild type RT in the range of 4 to 14% 
acetonitrile and also from 16 to 20% acetonitrile. As seen in the analogous fluorescence 
experiment, the two mutants are closer to each other in their dissociation pattern than to 
wild type RT. Also, as seen before, mutant L289P shows a greater deviation from wild
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Figure 45. RT polymerase activity analysis of the dissociation of subunits in 
increasing concentrations of acetonitrile. As the percentage of acetonitrile in the sample 
increases, the activity decreases due to the dissociation of the subunits. The results for 
all three forms of RT are shown in the graph.
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type RT behavior than does mutant L289R. These results support the observations from 
the previous experiment that both mutants dissociate into monomers more easily than wild 
type RT, and that mutant L289P dissociates into monomers more readily than mutant 
L289R.
Analytical Gel filtration Analysis of the Dissociation of RT Subunits in 8% 
Acetonitrile
Tandem HPLC gel filtration columns were used to observe the shift in percentage 
of monomers versus dimers when RT is incubated in acetonitrile. This experiment 
supports the fluorescence and activity observations that acetonitrile causes the RT subunits 
to dissociate without denaturing them. The fluorescence studies showed a 50% dis­
sociation of subunits for both mutant enzymes in 8% acetonitrile, so this concentration of 
acetonitrile was used for the gel filtration analysis. The RT sample was incubated in aceto­
nitrile as described for the fluorescence and activity assays to give a final concentration of 
8% acetonitrile. Figure 46A shows the gel filtration chromatogram offor mutant L289R 
that has not been incubated in acetonitrile. The dimeric form of the enzyme, p66/p66, 
elutes at 77.02 minutes and the monomeric form, p66, elutes at 87.76 minutes. Gel 
filtration analysis of mutant L289R that was incubated in buffer without acetonitrile shows 
that 47% of the enzyme was in dimeric form and 53% was monomeric. It is not surprising 
that the enzyme is slightly more monomeric than dimeric. Rowley and coworkers (27) 
found purified p66 RT to be an equilibrium mixture of monomers and dimers, and that p66 
from frozen stock solutions contained only 36% to 39% dimers. The mutant L289R which 
eluted from the gel filtration column after 77 minutes had been at room temperature for a 
total of 87 minutes in a buffer that did not contain glyceral or detergents which are normally 
used to help stabilize the protein. The buffer which contained only 50mM Tris-Cl pH 7.5 
and lOOmM KC1 was used for the HPLC gel filtration studies because it resulted in better 
resolution of monomer and dimer peaks. Figure 46B shows mutant L289R that has been
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Figure 46. HPLC gel filtration analysis of mutant L289R. Panel A: chromatogram of 
mutant L289R eluted in 50mM Tris-Cl pH 7.5/100mM KC1, no acetonitrile is present in 
the elution buffer or in the sample. 47% of the mutant RT elutes in the dimer peak at 
77minutes and 53% elutes in the monomer peak at 87.8 minutes. Panel B: 
chromatogram of mutant L289R which has been incubated in and eluted in 8% 
acetonitrile buffer. The dimer peak now makes up only 25% of the enzyme and 75% is 
monomeric, indicating that 47% of the dimers dissociated into monomers.
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incubated in 8% acetonitrile. This chromatogram show that the dimer peak makes up only 
25% of the enzyme so that 75% is monomeric. These results demonstrate that in the 
presence of 8% acetonitrile almost half of the dimerized enzyme dissociates into monomers. 
As can be seen in this chromatogram, both monomer and dimer peaks eluted 3 minutes later 
than enzyme which had not been incubated in acetonitrile. This shift may be due to 
changes in the 3-dimensional structure of the protein caused by the acetonirile even in 
subunits that remained dimerized. To confirm that both peaks contained the enzyme, the 
fractions containing these peaks were collected and analyzed by SDS-PAGE as shown in 
Figure 47.
Fluorescence Studies o f the Re-Association of RT Subunits After 
Dissociation with 17% Acetonitrile
In order to determine if the mutations had any effect on the ability of the subunits to 
dimerize, the samples were first completely dissociated with 17% acetonitrile and then 
observed over time for changes in fluorescence as the subunits re-associated. This process 
of re-association has been shown to occur the same way as subunits that have been 
separately purified and are combined for the first time without having ever been exposed to 
acetonitrile (29). This method of observing association of subunits, or dimerization, using 
fluorescence has already been used to analyze catalytic rates of association for wild type RT 
(32). For this experiment the association rate of wild type RT was compared with the 
association rate of mutants L289R and L289P over a period of 1 hour as shown in Figure
48. As time progresses from 0 to 60 minutes, the relative fluorescence of all three samples 
decreases, indicating that the subunits of the enzyme are forming dimers. The graph shows 
that all three samples take 50 to 55 minutes to completely dimerize. The rate of association 
for each enzyme sample was calculated from the slope of each sample curve and is 
expressed in Table 2 as relative fluorescence units per minute. The graph in Figure 48 
shows there are several points on the wild type RT curve that are significantly different
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Figure 47. Photograph of the silver stained, TCA precipitated fractions from 
HPLC gel filtration of mutant L289R. The gel shows that a 66KDa protein is in 
both peak fractions.
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
108
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
Figure 48. Fluorescence analysis of the re-association of subunits after dissociation 
with 17% acetonitrile. After initial dissociation of subunits, the concentration of 
acetonitrile was reduced 10 fold by dilution with fluorescence buffer which allows the 
subunits to reassociate to form dimers. The association rates are compared over a 
period of one hour. Panel A shows mutant L289R compared with wild type RT5. 
Panel B shows mutant L289P cor red with wild type RT5.
•  Wild Type RT5 Mutant L289R M  Mutant L289P
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Table 2. Association rates of wild type RT, mutant L289R, and mutant 
L289P. Rates were calculated from die data of fluorescence analysis of the re­
association of subunits over time.
K
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Enzyme Sample Relative Fluorescence Units
Per Minute




Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
from both mutant RT curves. This indicates that wild type RT is associating more rapidly 
than either of the two mutants. It also appears that there may be a slight difference between 
the two mutants during the early stages of the dimerization process. When the association 
rate was calculated based on the slope of the line, the calculations support these 
observations that wild type RT associates faster than either mutant with an association rate 
of 0.017 relative fluorescence units per minute, and that mutant L289R, which associates at
0.018 fluorescence units per minute, associates faster than mutant L289P which has a rate 
of 0.019 fluorescence units per minute.
Effect of L289 Mutations on RNase H Activity
The mutants were compared to wild type RT in their ability to degrade the RNA of 
the tritiated RNA-DNA hybrid as shown in Figure 49. A negative control sample in which 
no enzyme was added was run along with the HIV-1 RTs. AMV RT was run as a positive 
control. As time progressed, the RNA in the samples which received RT enzyme was 
degraded resulting in decreased CPMs, whereas the control sample, which did not receive 
any enzyme, did not show a decrease in CPMs. All samples which received enzyme were 
degraded to background levels after 60 minutes. Mutant L289P was not significantly 
different from mutant L289R in RNase H activity, and neither mutant was significantly 
different from wild type RT in this activity.
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Figure 49. RNase H activity assay of mutant RTs and wild type RT plus a negative 
control (no enzyme) and a positive control (AMV RT). Counts per minute (CPM) 
indicate the amount of DNA-RNA hybrid that is trapped on the nitrocellulose filters 
because it was not degraded by RT RNase H activity.
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DISCUSSION
Two HIV-1 RT mutants have been created using PCR mutagenesis and 
recombinant DNA techniques. These mutants were expressed in yeast and purified using a 
cation exchange column, an affinity column, an FPLC gel filtration column, and an HPLC 
gel filtration column. The presence of RT in the purified sample was confirmed using RT 
activity assays and SDS-PAGE. The two mutants were compared to each other and to wild 
type RT in terms of specific activity, subunit dissociation, and subunit association using 
RT polymerase activity assays, fluorescence studies, and analytical gel filtration. Both 
mutants showed less specific activity than wild type RT, both mutants dissociated into 
monomers more easily than wild type RT, and both mutants were slower to associate to 
form dimers than wild type RT. In addition, the two mutants differed from each other in 
each of these activities. The L289P RT mutation had a greater affect on subunit interactions 
than the L289R mutation. Consequently, the L289P mutant dissociated more quickly in the 
presence of acetonitrile and was slower to re-associate once the acetonitrile was diluted to a 
non-denaturing concentration than mutant L289R. These results raise the following 
questions: 1) why did the mutations affect dimerization only partially and not cause them to 
completely dissociate? 2) why did the mutation L289P have a greater affect on subunit 
interactions than the L289R mutation? and 3) how do these results compare to the results of 
other researchers who also made mutations in this region? In order to answer these 
questions it is helpful to go back and consider why these mutations were made.
This research was undertaken because we wanted to leam more about where and 
how subunit interactions take place. The mutations that were created were chosen because
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they changed amino acids which were believed to be directly involved in dimerization. 
Previous research had narrowed down the possible regions involved in subunit interactions 
to three different locations, all of which were believed to lie in a hydrophobic interface 
which was not accessible to monoclonal antibodies when the subunits were dimerized (39). 
The first region was from amino acid 230 to 300 (39), which includes a leucine repeat 
sequence (38). The leucine repeat sequence in this region was of particular interest because 
it is very similar to the leucine zipper, a protein-DNA binding motif which enables either 
two proteins or two subunits of a protein to bind together and at the same time bind DNA. 
Most of these DNA binding proteins are DNA transcription factors, but it is also a logical 
binding method for a DNA polymerase dimer in which the subunit binding is known to 
involve hydrophobic interactions. It also makes sense that, in the case of RT, the protein- 
DNA binding should be flexible enough to allow the complex catalytic activity of DNA 
polymerization and RNA degradation. This would explain why the leucine repeat sequence 
in RT was not a strictly conserved leucine zipper. In a strict leucine zipper motif, two a  
helices, one from each monomer, are joined by hydrophobic interactions of leucines at 
every eighth residue on each subunit (77). HIV-1 RT differs from the classical leucine 
zipper in that it has a threonine in place of one of the leucines and it has a proline in the 
middle of the motif. Goel and coworkers, as well as my own sequence comparison 
studies, found the leucine repeat sequence to be conserved among different isolates of HIV- 
1 RT (40). The second region included amino acids 350 to 428 (39) which contains a large 
number of tryptophan residues which may also be involved in subunit interactions because 
they have hydrophobic side chains (75). This theory was further supported by the 
fluorescence studies of Divita and coworkers (32) who observed a 25% increase in intrinsic 
fluorescence as dimers dissociated into monomers due to the exposure of tryptophan 
residues. The third region included amino acids around 540 which is in the RNase H 
domain (75). This region has been shown to be involved in the interaction between the 
RNase H domain and the polymerase domain (76). The RNase H region around 540
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contains two metal binding sites and it has been shown that the presence of Mg2+ increases 
the association rate of the heterodimer by 100 fold (32). It was suggested that binding of 
magnesium may result in a conformational change which favors dimerization (32).
The research described in this paper was undertaken because it was theorized that 
the region between amino acids 230 and 300 containing the leucine repeat sequence was 
essential for subunit binding, and much of the evidence indicating the involvement of other 
regions in dimerization had not yet been published. However, the results presented in this 
paper show that this region is not directly responsible for dimerization because it was found 
that the mutations only partially affected subunit interactions and did not completely inhibit 
them. Dimerization of the subunits was not prohibited by a mutation in the leucine repeat 
region because one or more of the other regions described above is probably also involved 
in subunit binding. Also, the leucine repeat region may be more important for intra­
molecular hydrophobic interactions which maintain the tertiary structure of the molecule 
and enable the subunits to associate properly so that subunit binding in other regions can 
take place. The data in this study suggests that the leucine repeat sequence is important for 
hydrophobic interactions; however, it is probably not the primary subunit binding region.
Another interesting question that this research raises is why the L289P mutation had 
a greater effect on subunit interactions than the L289R mutation? In order to decide which 
amino acid changes to make, a computer program was used called Mac Vector 3.5 which 
draws profiles of proteins based on the amino acid sequence of the protein and the chemical 
characteristics of each residue (78). For example, a hydrophilicity profile is determined by 
assigning each amino acid a "hydropathy" value based on the Kyte and Doolittle 
hydropathy scale (79) and using this value to determine the average hydrophilicity per 
residue for the protein (78). The hydrophilicity profile of wild type RT and the different 
L289 mutants is shown in Figure 50 and the site of the changed amino acid is circled in 
each case. As can be seen in this Figure, mutants L289R and L289P are different
115
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Figure 50. Hydrophilicity profile drawn by MacVector computer program based on 
amino acid sequence characteristics. The RT sequence from amino acid 269 to 311 is 
shown for wild type RT (Panel A), mutant L289R (Panel B), and mutant L289P (Panel 
C). Amino acid 289 is circled showing where the site-specific mutation was made. 
Positive values are hydrophilic and negative values are hydrophobic.
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from wild type RT but similar to each other. The L289R mutation has a slightly greater 
effect on the hydrophilicity profile than the L289P mutation. If hydrophobic interaction 
was the most important factor in the subunit interaction, then one might expect the L289R 
mutation to have a greater effect on dimerization than the L289P mutation which would be 
the opposite of what was actually observed. Surface probability is calculated by the 
MacVector program based on studies by Janin and coworkers (80) which assign each 
amino acid a percent exposed or percent buried value. These values were used by Emini et 
al. (81) to calculate a fractional surface probability for each amino acid, which MacVector 
uses to determine a running average of the fractional surface probability along the length of 
the protein (78). Figure 51 shows the surface probability calculations for wild type RT and 
mutants L289R and L289P. The results are similar to the results for hydrophilicity which 
is not surprising since surface probability takes into consideration the hydrophilicity or 
hydrophobicity of amino acids. As can be seen in Figure 51, the two mutants have similar 
profiles to each other but again are different from the wild type RT, and the L289R mutant 
shows a slightly greater difference than L289P. When the computer was asked to predict 
features of secondary structure some different results were obtained. Secondary structure 
predictions are carried out using a combination of two methods, the Chou-Fasman method 
(82) and the Robson-Gamier method (83), which are each graphed separately followed by 
a graph of consenting results from both methods. The Chou-Fasman method assigns each 
amino acid to one of four classes: helix formers, helix breakers, sheet formers, or sheet 
breakers, based on statistics of known x-ray crystal studies. These classifications are used 
to locate regions of helix or sheet forming residues which are assigned weights in order to 
calculate their significance (82). Predictions using this method may vary depending on 
how different programmers use weight calculations (78). The Robson-Gamier method is 
more clearly defined and should not vary among different program applications (83,78). 
MacVector's application of this method determines the tendency for a given residue to be a 
part of either an alpha helix, a beta sheet, or a turn. Figure 52 shows the results of the
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Figure 51. Surface probability profile drawn by MacVector computer program based on 
amino acid sequence characteristics. The RT sequence from amino acid 269 to 311 is 
shown for wild type RT (Panel A), mutant L289R (Panel B), and mutant L289P (Panel 
C). Amino acid 289 is circled showing where the site-specific mutation was made. Values 
greater than 0.50 represent amino acids that are more likely to be at the surface of the 
protein and values less than 0.50 are amino acids that are more likely to be buried.
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Figure 52. Secondary structure profile drawn by MacVector computer program based on 
amino acid sequence characteristics. The RT sequence from amino acid 269 to 311 is 
shown for wild type RT (Panel A), mutant L289R (Panel B), and mutant L289P (Panel 
C). Amino acid 289 is circled showing where the site-specific mutation was made.
CF = Chou-Fasman predictions for helix, sheet, or turns 
RG = Robson-Gamier predictions for helix, sheet, or turns 
CFRG = consensus predictions for helix, sheet, or turns
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secondary structure profiles for wild type RT and the two mutants. As can be seen in this 
figure, the structure of an L289R mutant was predicted to be similar to that of wild type 
RT, whereas the structure of the L289P mutant was predicted to be significantly different. 
It is possible that the proline residue, an amino acid which is usually found in the bends of 
large folded proteins, changed the secondary structure enough to hinder association of 
subunits and enhance dissociation of subunits in acetonitrile. Taken together, the predicted 
effects of the mutations help explain the observed results. Both L289R and L289P mutants 
differed from wild type RT in their hydrophilicity profile, but L289P also differed in 
secondary structure effects. Consequently, both mutants could have affected subunit 
interactions by disrupting the hydrophobic interface, but mutant L289P had an additional 
effect on secondary structure by inserting a kink in the amino acid chain which made it 
more difficult for the subunits to come together.
How do the results of this research compare with the research of Goel and 
coworkers (40) who also mutated leucine 289 of RT? They changed the leucine to a lysine 
in both the p66 subunit and the p51 subunit. These researchers used gel filtration, 
ultracentrifugation, circular dichroism analysis, and RT activity assays to analyze the 
effects of the mutations on dimerization. They found that the L289K mutation in the p51 
subunit did not affect dimerization or RT activity but that the L289K mutation in the p66 
subunit greatly reduced RT activity and dimerization. The apparent molecular weight as 
judged by SDS-PAGE was the same for wild type and mutant forms of RT. However, 
from circular dichroism spectroscopy they concluded that mutants L289K-p66 and L289K- 
p51 were structurally similar but not identical to their wild type homologues and that 
L289K-p66 showed a greater difference from wild type p66 than L289K-p51 from wild 
type p51. It is interesting, although not surprising, that the mutant which showed the 
greatest difference in structure from the wild type species was also the mutant which had 
the greatest effect on dimerization. Since our lab does not have the capability of circular 
dichroism spectroscopy, the results of the Goel study could not be directly compared to
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ours on the basis of this technique. However, it would be expected that our L289R-p66 
mutant would not show as great a difference in structure from wild type p66 as Goel 
observed for their L289K-p66 mutant since the activity of L289R-p66 was not as different 
from wild type p66 as Goel observed for L289K-p66. Based on SDS-PAGE analysis and 
analytical gel filtration, both of our p66 mutants migrated the same distance and eluted at 
the same time as wild type p66, indicating that not only the molecular size was the same, 
but also the three dimensional shape of the molecule was very similar. Molecules of the 
same size but different shape will migrate at different rates through a molecular sieve, for 
example, a globular molecule will run faster than a linear molecule of the same size. Using 
analytical gel filtration, the Goel study looked at dimerization of L289K-p51 with wild type 
p66 and with L289K-p66, as well as L289K-p51 by itself. They also looked at L289K- 
p66 with wild type p51 and they found that all of these combinations produced only 
monomer species except wild type p66 with L289K-p51, demonstrating that mutant 
L289K-p66 was not able to dimerize. These researchers did not use analytical gel filtration 
to study L289K-p66 homodimerization. However, they did use analytical ultracentrifu­
gation to look at L289K-p66, and their results suggested that the polypeptide was a 
homogeneous monomer (40). For the research presented in this paper, L289R-p66 and 
L289P-p66 were analyzed using analytical gel filtration and intrinsic fluorescence studies 
for homodimerization only. Each mutant showed a decrease in the ability to dimerize with 
itself as compared to wild type p66, however they did dimerize. There are many possible 
reasons for the difference between the results presented here and the results observed in the 
Goel study. First of all, their p51 RT construct is 15 amino acids shorter than our p51, 
which terminates at the same amino acid residue as that generated by cleavage by HIV 
protease in vivo (11). Another difference is that their activity assay is carried out at 25°C 
for 10 minutes, while ours is at 37°C for 30 minutes. Their assay conditions may be 
suitable for wild type RT but not for the mutant RT. Also, the activity of the mutants was 
expressed as a fraction of wild type RT activity instead of specific activity as in our results.
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Another difference is that they used a different buffer for analytical gel filtration and 
samples were incubated at 30°C for 2 hours before injecting them on the column. RT is 
very sensitive to changes in pH, temperature, ionic strength, and enzyme concentration. 
Goel and coworkers conclude that the leucine repeat sequence in the p66 subunit only is 
directly involved in and essential for subunit binding and enzyme activity of HIV-1 RT. 
Our evidence shows that the leucine repeat sequence is not essential for subunit binding 
and, although it is important for maintaining enzyme structure and activity, it would not be 
a good target for designing anti-HIV therapy. Certainly more research needs to be done in 
order to understand subunit binding, and to design a method of inhibiting it which would in 
turn inhibit enzyme activity. In the case of our mutants, more studies need to be done 
using the wild type p51 subunit to determine the effect of the p66 mutation on 
heterodimerization. Also, it would be useful to create the same mutations in the p51 
subunit to determine if the role of this residue in this subunit is different than it is in the p66 
subunit. Since this research implies that other regions of RT are more important for 
subunit binding it would be desirable to try mutations in these other regions. It may be that 
subunit binding involves several residues so that a single amino acid change is not enough 
to characterize such a complex protein-protein interaction. More studies need to be done on 
the effect of pH and ionic strength on dimerization. Since dimerization is essential for 
enzyme activity, this is still an important area for research to combat AIDS.
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